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decided to analyze the rate of progression of CKD in a population followed
by a multidisciplinary team.
Methods: We analyzed data from 209 patients (102 females) referred to the
Nephrology Division, after at least 6 months under treatment by a multi-
disciplinary team (nephrologist, nutritionist, nurse and psychologist) patients
were followed from January of 2002 until December of 2005. Glomerular
filtration rate was estimated by MDRD equation (eGFR). Patients with
eGFR below 15ml/min were excluded, and this value was considered the
end-point for calculation of the rate of decline of renal function. Results are
mean± SD.
Results: Hypertension was the main cause of CKD (31%) followed by Di-
abetes (26%). Age was 60±15 years, body mass index was 27±5 kg.m2 for
females and 26±4 kg.m2 for males. Serum calcium, phosphorus and albumin
were normal. Urea was 71±36mg/dl, eGFR = 38±20 ml/min. Systolic ar-
terial pressure was 137±20mmHg and diastolic= 80±11mmHg; hematocrit
= 37±5%, hemoglobin =12.3±1.7g/dl; cholesterol= 194±42mg/dl, HDL-
cholesterol= 36±11mg/dl, LDL-cholesterol= 119±54mg/dl; triglyceride =
167±106 mg/dl; iPTH= 221±221 pg/ml.
From the studied population 58% was referred to treatment with eGFR =
45-30 ml/min, and the remaining with eGFR =29 to 15 ml/min.
K/DOQUI suggests a decline of 4ml/min/year for CKD patients. As shown
in Table1, the rate of decline of eGFR of the present population was below
this level, meaning an extra gain of time per year free from dialysis as a
consequence of the conservative management with a multidisciplinary team.
Table1. Progression of CKD
Baseline disease Initial eGFR GFR reduction Time expectancy Time gain/year
(ml/min) (ml/min/yr) in conservative in conservative
management (yrs) management (yrs)
Diabetes 40.48 2.88 8.85 0.62
Hypertension 35.41 0.89 23.05 0.78
Others 46.21 1.23 25.42 0.69
Conclusions: The present data show that a late referral population, did not
show complications of uremia, and the rate of decline of GFR was lower
than suggestted by K/DOQUI. We concluded therefore that, if followed
by specialists and if possible by a multidisciplinary team, retarding the
progression of CKD even in its more advanced stages is possible. Therefore
conservative management is an efficient way to maintain CKD patients and
to postpone renal substitutive therapy. Finally we believe that programs
aiming this treatment should be encouraged to ameliorate care of CKD
patients.
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FP158 ETHNIC DIFFERENCES IN PREVALENCE OF
HEMATOLOGICAL AND METABOLIC ABNORMALITIES BY
GFR STAGE
S. Barbour 1, L. Er 2, O. Djurdjev 2 , M. Karim 3, A. Levin 1. 1Division of
Nephrology, University of British Columbia, Vancouver, BC, Canada;
2Health Care and Epidemiology and BC Renal Agency, University of
British Columbia, Vancouver, BC, Canada; 3Royal Columbia Hospital,
Vancouver, BC, Canada
Introduction and Aims: Biochemical and hematological abnormalities
increase in severity and prevalence by stage of GFR. The evidence to
date is based on NHANES data from a US cohort of white, black and
Hispanic ethnicities. Using a provincial database in which all patients
referred nephrologists are registered when GFR< 60ml/min, we undertook
to describe the prevalence of abnormalities by ethnicity within different
levels of GFR.
Methods: British Columbia is a population of 4 million people, with mixed
ethnicities including Caucasian, Oriental Asian, South Asian and First
Nations individuals. Between 2000 and 2006, we examined a registered
cohort of 5968 pts who had GFR < 60 ml/min/1.73 m2, to determine
the prevalence of abnormalities in hemoglobin, calcium, phosphate, iPTH,
albumin and bicarbonate at the time of registration. Cut-off-points were
selected based on the lower or upper limit of the lab normal range. GFR
was calculated using the abbreviated MDRD formula, and using categories
of <15, 15-30, 30-45 and 45- 60 ml/min.
Results: The mean age of our cohort was 66; 57% were male, and 38%
were diabetic. The proportion of patients within each category of GFR was
similar by ethnicity: Caucasian 65-77%, Asian Oriental 8-17%, South Asian
7-10%, Other 3-6%. Table 1 describes the prevalence (%) of abnormalities
of hematological and metabolic abnormalities by ethnicity and level of
GFR. Note that there is statistically different prevalence of abnormalities
within stages of GFR between Caucasians and Asian Orientals in particular.
Table 1. Prevalence of hematological and metabolic abnormalities by ethnicity and
GFR level
GFR Level Caucasian Asian Oriental South Asian† Others
N 4301 820 552 295
Age (yrs) 67±15 67±16 60±17 56±18
Male (%) 59 52 54 51
Diabetes (%) 38 28 47 46
GFR 26.5±13.1 22.7±12.2 24.1±13.2 23.6±13.8
HG<120 g/L [45 - 60) 31 51* 43 30
[30 - 45) 39 49* 48 59
[15 - 30) 52 58* 63 61
<15 64 64 55 60
CA<2.1 [45 - 60) 8 15 2 21
[30 - 45) 6 15* 7 17
[15 - 30) 13 21* 16 28
<15 14 25* 16 35
PO4>1.4 [45 - 60) 14 19 20 30
[30 - 45) 18 32* 29 30
[15 - 30) 35 42* 49 47
<15 57 55 59 57
iPTH>6.8 [45 - 60) 39 53 47 48
[30 - 45) 53 53 79 67
[15 - 30) 66 62 76 69
<15 65 74 79 71
ALB<35 g/L [45 - 60) 16 23 12 27
[30 - 45) 15 20* 13 33
[15 - 30) 23 32* 32 37
<15 42 44 25 45
HCO2<20 [45 - 60) 2 4 2 3
[30 - 45) 6 7 6 17
[15 - 30) 9 10 11 17
<15 13 13 16 15
†Asian Indian and Filipino; *indicates statistically significant compared to Caucasian
Conclusions: This is the first report of differential prevalence of well-
known renal associated abnormalities by ethnicity within a patient cohort
in a universal access health care system. Improved understanding of these
differences are important in order to understand the pardoxical finding of
better prognosis for Asian Orientals on dialysis. These findings indicate
that this occurs in spite of worse metabolic and hematologic abnormalities
at earlier stages of CKD. Questions around race specific GFR and related
laboratory test cut-offs should be pursued.
FP159 PREDICTORS OF NEW-ONSET KIDNEY DISEASE IN A
GENERAL MIDDLE-EUROPEAN POPULATION
Rudolf P. Obermayr 1, Christian Temml 2, Maarten Knechtelsdorfer 1,
Georg Gutjahr 3, Josef Kletzmayr 1, Susanne Heiss 1,
Renate Klauser-Braun 1. 1Donauspital im Sozialmedizinischen Zentrum Ost
der Stadt Wien, 3rd Medical Department, Vienna, Austria; 2Department of
Health Prevention, Vienna, Austria; 3Vienna University of Technology,
Institute of Statistics and Probability Theory, Vienna, Austria
Introduction and Aims: Established cardiovascular risk factors are associ-
ated with end-stage renal disease (ESRD) with hypertension and diabetes
being the leading causes. The aim of this study was to identify risk factors
at an earlier stage of kidney disease with the belief that interventions could
prevent or delay the progression to ESRD as well as cardiovascular disease.
Predictors of new-onset kidney disease have not been thoroughly studied.
Methods: Since 1990 the general population of Vienna was invited to
yearly preventive medical checkups within the ongoing Vienna Health
Study. Until 2005, 24.689 apparently healthy volunteers (44% women, age
range 20-84 years, men 20-89 years) could be assessed longitudinally.
They performed a baseline examination at any time within the study period
and were subsequently invited to a follow up examination once a year,
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but no preset time intervals for the follow up examinations could be
demanded imperatively. Within the follow up period, there were a mean of
3.09 individual follow up examinations performed, each individual’s mean
follow up period was 5.66 years and the mean longest follow up period
was 7.44 years. Primary outcome of interest was the development of kidney
disease defined as a decrease of glomerular filtration rate (GFR) < 60
ml/min/1.73m2 (calculated by the abbreviated Modification of Diet in Renal
Disease (MDRD) -equation) at the follow up examinations. Covariates
included age, sex, GFR, body mass index, sports (endurance exercise ≥ 2
times/week), smoking status, total-, HDL-, LDL-cholesterol, triglycerides,
uric acid, fasting serum glucose, systolic and diastolic blood pressure,
diagnosis of hypertension categories, and diabetes mellitus. A multivariable
logistic generalized estimating equations model (taking into account the
dependence between repeated measurements within the same individual
at different follow up periods) was performed with respect to statistical
significance resulting from univariate analysis of the covariates adjusted for
age and sex. Variables were retained if Wald tests gave a P < 0.001.
Results: The following parameters presented as odds ratios (OR) with 95%
confidence intervals predicted new-onset kidney disease: Age (increase of
5 years), OR=1.35 (1.33 to 1.37); sex if female, OR=1.91 (1.70 to 2.16);
MDRD-GFR ≥ 90 ml/min/1.73m2 vs. 60-89 ml/min/1.73m2, OR=0.54
(0.50 to 0.73); sports, OR=0.64 (0.57 to 0.73); smoker, OR=1.69 (1.54 to
1.85); ex-smoker, OR=1.38 (1.22 to 1.56); uric acid (increase of 2 mg/dl),
OR=1.71 (1.60 to 1.83); hypertension stage 1, OR=1.78 (1.60 to 1.99);
hypertension stage 2, OR=2.28 (1.99 to 2.61); diabetes mellitus, OR=1.52
(1.11 to 2.10).
Conclusions: Established cardiovascular risk factors predicted new-onset
kidney disease. The impact of sex should be interpreted retentive, since sex
appears in the numerator of the MDRD-equation. Higher GFR at baseline
and sports were revealed as probably protective.
FP160 CHRONIC KIDNEY DISEASE AND MORTALITY AND
MORBIDITY AMONG PATIENTS WITH ESTABLISHED
CARDIOVASCULAR DISEASE: A COMMUNITY-BASED
COHORT STUDY
Liam Glynn 1, Donal Reddan 2, John Newell 3, John Hinde 3,
Brian Buckley 1, Andrew Murphy 1. 1Department of General Practice,
National University of Ireland, Galway, Ireland; 2Department of
Nephrology, National University of Ireland, Galway, Ireland; 3Department
of Mathematics, National University of Ireland, Galway, Ireland
Introduction and Aims: The importance of chronic kidney disease as
an independent risk factor for morbidity and mortality in patients with
cardiovascular disease in the community is not widely recognised.
Methods: A retrospective cohort study based in the West of Ireland followed
a randomised practice-based sample of patients with cardiovascular disease.
A database of 1,609 patients with established cardiovascular disease was
established in 2000. This was generated from a randomised sample of 35
general practices in the West of Ireland. The primary end point was death
from any cause. The secondary endpoint was a cardiovascular composite
endpoint which included death from a cardiovascular cause or any of the
cardiovascular events of myocardial infarction, heart failure, peripheral
vascular disease and stroke.
Results: Of the original community-based cohort of 1,609 patients with
cardiovascular disease, 1,272 (79%) had one or more serum creatinine
measurements during the study period and 31 (1.9%) patients were lost
to follow-up. Median follow-up was 2.90 years (SD 1.47) and the risk of
death from any cause [total of 214 deaths] was significantly increased in
those patients with reduced estimated GFR (glomerular filtration rate) [Log
Rank (Mantel-Cox) 56.97, p < 0.000] as was the risk of the cardiovascular
composite endpoint (Log Rank (Mantel-Cox 26.74 p < 0.000). For every
10ml decrement in estimated GFR there was a corresponding 33% increase
in relative risk of death from any cause and a corresponding 20% increase
in relative risk of the cardiovascular composite endpoint.
Conclusions: Estimated GFR appears to discriminate prognosis between
patients with established cardiovascular disease. These results emphasise
the importance of recognising chronic kidney disease as a significant and
potentially modifiable risk factor in patients with cardiovascular disease in
the community.
FP161 SYSTEMATIC ESTIMATION OF GLOMERULAR
FILTRATION RATE IN PRIMARY CARE PATIENTS AND ITS
INFLUENCE IN NEPHROLOGY REFERRAL
Pedro Jesus Labrador 1, Jorge Labrador 2, Teresa Mengotti 3,
Montaña Jimenez 3, Javier Martin-Oncina 3. 1Nephrology, Hospital Virgen
del Puerto, Plasencia, Caceres, Spain; 2Facultad de Medicina, Universidad
de Salamanca, Salamanca, Spain; 3Clinical Analysis, Hospital Vigen del
Puerto, Plasencia, Caceres, Spain
Introduction and Aims: Chronic kidney disease (CKD) is becoming a
public health burden. The ageing population and the epidemic of type 2
diabetes are the main causes. Early detection of renal dysfuntion is critical to
its clinical management. Many factors affect serum creatinine concentration
so creatinine-based equations are recommended to estimate glomerular
filtration rate (GFR). The aim of this study was to know the number of
CKD patients attended in primary care and the influence of systemic GFR
estimation in nephrology referral.
Methods: This is a six months descriptive study. GFR was estimated using
the modified MDRD formula in all primary care patients over 18 years living
in the reference area of our Hospital, in who serum creatinine concentration
were asking for their primary care doctor. Kidney function was classified by
the K/DOQI stages. We also examined cholesterol and haemoglobin levels,
as well as the presence of hyperglycaemia when were available.
Results: GFR was estimated in 16167 analysis. GFR <60mL/min/1.73m2
was present in 1254 analysis from 1094 patients (6.8% of total analysis),
70.7% women. These patients aged 40 to 98 years (mean 77±9), serum
creatinine was 1.3±0.6 mg/dL and GFR 48.5±10 mL/min/1.73m2. Accord-
ing to K/DOQI stages, 93% were at stage 3, 6.5% at 4 and 0.5% at 5.
Glycaemia >126 mg/dL was found in 18.5% and >100 mg/dL in 10.4%,
LDL-cholesterol levels >100 mg/dL was present in 54.6% and anemia
(haemoglobin <13 g/dL in men or <12 g/dL in women) exist in 20.9% of
patients with GFR <60mL/min/1.73m2.
131 patients (12%) were nephrology referral during the study period or 3
months later. Referred patients versus non-referred patients characteristics
are showed in Table 1.
Referred patients versus non-referred patients data
Referred patients Non-referred patients p
(n=131) (n=963)
Age (years) 73.5±9.7 77.4±8.8 <0.0001
Sex (%women) 50.4% 73.5% <0.0001
Creatinine (mg/dL) 1.68±0.72 1.29±0.52 <0.0001
GFR (mL/min/1.73m2) 41.3±11.8 49.5±9.3 <0.0001
Cholesterol (mg/dL) 189.9±49.4 199.8±42.3 0.042
LDL-c (mg/dL) 110.3±42.5 115.9±35.9 NS
LDL-c <100 mg/dL (%) 33.6% 27.9% 0.01
Diabetes mellitus (%) 19.1% 18.4% NS
Haemoglobin (g/dL) 13.1±2 13.5±1.7 0.03
Anemia (%) 38.4% 18.6% <0.0001
Data are mean ± SD, except where specified. NS: not significative. Anemia was
defined as haemoglobin <13 g/dL in men and <12 g/dL in women.
Conclusions: In our primary care population, we found a prevalence of
CKD near 7%, mostly women aged 70 to 80 years. Patients with GFR
<60mL/min/1.73m2 have a high prevalence of hypercholesterolemia and
anemia, and 18.5% were diabetics.
Only 12% of patients with CKD were nephrology referral. This patients
were younger, present lower GFR with higher creatinine levels and worse
control of LDL-cholesterol and anemia than non-referred.
So we thought GFR estimation improved nephrology referral.
FP162 DIFFERENTIAL ASSOCIATION OF METABOLIC
SYNDROME (MS) AND CHRONIC KIDNEY DISEASE
(CKD) BETWEEN MEN AND WOMEN IN KOREA:
RESULTS FROM KOREAN NATIONAL HEALTH AND
NUTRITION EXAMINATION SURVEY (KOREAN
NHANES)
M.A. Yu, J.H. Ryu, D.R. Ryu, S.J. Kim, K.B. Choi, K.I. Yoon, D.H. Kang.
Nephrology, Ewha Womans University College of Medicine, Seoul, South
Korea
Introduction and Aims: Both MS and CKD are the major international
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health problem. Although MS is known to be strongly associated with CKD
in several cohort studies from different countries, it is not known which
components of MS are more important than others for the development of
CKD or which host factors play a significant part in the relationship between
MS and CKD. To better understand the complex interrelationship between
MS and CKD, we performed a cross-sectional study in non-institutionalized
Korean civilian using the data of Korean NHANES in 2001. The Korean
NHANES is a health survey of a nationally representative sample of the
Korean population.
Methods: Of 7,918 participants, 5,491 at age between 20 and 79 years
were available for analysis for the prevalence of CKD (defined as dipstick
proteinuria or a reduced GFR less than 60 ml/min per 1.73m2 by MDRD
formula). MS was diagnosed by NCEP-ATP III with the Asia-Pacific
abdominal obesity criteria (90 cm for men, 80 cm for women).
Results: The prevalence of CKD was in 8.7% of subjects (7.2% in men and
9.9% in women) and MS was seen in 25.7% (24.4% in men and 26.8% in
women). The prevalence of CKD increased with age, especially in 60 years
of age and over sharply in both genders. Although MS was a significant
determinant of CKD in entire subjects [OR=1.68 (95% CI 1.36-2.09),
p=.000], subanalysis revealed that it was only significant in younger men
(<60 years) [OR=2.49 (1.50 to 4.12, p=.000) in men<60, OR=1.04 (0.59 to
1.82, p=0.89) in men≥60, OR=1.09 (0.69 to 1.72, p=0.73) in women<60,
OR=1.44 (0.95 to 2.17, p=.08) in women≥60]. This finding suggested that
MS was no more a significant determinant of CKD after age of 60 despite
a high prevalence of MS per se in this age group. Among five risk factors
of MS, all five components affected CKD in men<60 years [impaired
fasting glucose: OR=3.08 (1.94 to 4.89, p=0.000), high TG: OR=2.69 (1.71
to 4.25, p=0.000), hypertension: OR=2.65 (1.70 to 4.11, p=0.000), central
obesity: OR=2.41 (1.54 to 3.77, p=0.000), low HDL: OR=1.67 (1.08 to
2.58, p=0.02)] whereas only central obesity, hypertension and high TG
related to CKD in women<60 years [central obesity: OR=1.60 (1.13 to
2.27, p=0.008), hypertension: OR=1.80 (1.22 to 2.66, p=0.003), high TG:
OR=1.50 (1.02 to 2.20, p=0.04)].
Conclusions: Metabolic syndrome was a significant determinant of CKD
in younger subject (<60 years), not in elderly population. In men, all five
risk factors of MS were important, but in woman, only central obesity,
hypertension and high TG were significant risk factors for CKD. In elderly
population, not MS but aging and other risk factors may take more important
part in the development of CKD.
FP163 UROTENSIN II IS AN INVERSE PREDICTOR OF DEATH
FROM ALL CAUSES AND CARDIOVASCULAR EVENTS IN
CHRONIC KIDNEY DISEASE STAGE 2-5
Pietro Ravani 1,2, Gianluigi Tripepi 3, Paola Pecchini 1,
Francesca Mallamaci 3, Fabio Malberti 1, Carmine Zoccali 3. 1Nephrology
and Dialysis, Azienda Istituti Ospitalieri di Cremona, Cremona, Italy;
2Clinical Epidemiology Unit, Faculty of Medicine, Memorial University of
Newfoundland, St. John’s, NL, Canada; 3CNR-IBIM, Clinical
Epidemiology & Pathophysiology of Kidney Diseases, Ospedali Riuniti di
Reggio Calabria, Reggio Calabria, Italy
Introduction and Aims: Urotensin II (UTN) is a cyclic vasoactive un-
decapeptide highly represented in multiple organ systems, including the
kidney and the cardiovascular (CV) system. Plasma levels of UTN are
much increased in end-stage renal disease (ESRD). However, despite its
vasculotoxic potential in animal models, higher plasma UTN predicts longer
survival in dialysis patients. We sought to determine if this same association
exists in earlier stages of Chronic Kidney Disease (CKD) studying an
incident cohort of 122 clinically stable pre-dialysis patients.
Methods: Linear models were used to study the associations of UTN with
baseline characteristics, renal function, traditional and non-traditional CV
risk factors including homocysteine and acute phase reactive proteins, and
previous history of CV disease (coronary artery, peripheral or cerebro-
vascular disease, or heart failure). Cox’s regression was used to model time-
to-death as a function of UTN considering the same covariates for adjustment
plus a time-varying variable indicating progression to ESRD (progressed to
ESRD vs. never/not yet progressed). Two separate models were built with
either time-to-death from all causes or fatal CV events as outcomes.
Results: Mean age at enrolment was 71±11 years, 64% of patients were
men, 24% diabetics and 58% had clinical CV disease. No correlation was
found between baseline GFR (mean 32±15 ml/min/1.73 m2) and plasma
UTN (mean 5±3.6 ng/ml). In this cohort, plasma UTN (median 4.4 ng/mL,
inter-quartile range: 2.0-7.4 ng/mL) was significantly higher (P<0.01) than
that in healthy subjects (median 2.8 ng/mL, inter-quartile range: 1.9-4.6
ng/mL). In adjusted analysis UTN correlated directly with serum albumin
(1.66 ng/ml per g/dL, P=0.004) and inversely with pre-existing coronary
artery disease (-1.66 ng/ml, P=0.01). During a mean follow-up of 41
months, 43 patients died, 29 from CV events. After adjusting for potential
confounding factors, increased UTN similarly predicted lower risk for death
from all and CV causes (Hazard Ratio 0.88; 95% Confidence Intervals
0.80-0.97). Both models included C-Reactive-Protein, previous history of
CV disease and the time-varying indicator of progression to ESRD as direct
predictor of death. None of the other clinical characteristics, comorbid
conditions, nontraditional and traditional CV risk factors considered were
significant at the two-tailed level of 0.05 or modified the regression
coefficient of UTN.
Conclusions: In patients with moderate to severe CKD plasma UTN is an
inverse predictor of overall and CV mortality. Our findings confirm data
observed in ESRD and suggest that UTN should not necessarily be viewed
as a vasculotoxic peptide in CKD patients.
FP164 CLINICAL PREDICTORS OF ATHEROSCLEROTIC
RENOVASCULAR DISEASE IN PATIENTS
UNDERGOING CARDIAC CATHETERIZATION
Carmelita Marcantoni 1, Luca Zanoli 2, Stefania Rastelli 2 ,
Giovanni Tripepi 3, Salvo Virzi 4, Domenico Di Landro 1,
Corrado Tamburino 4, Carmine Zoccali 3, Pietro Castellino 2 . 1Nephrology,
Cannizzaro Hospital, Catania, Italy; 2Internal Medicine and Nephrol,
University of Catania, Catania, Italy; 3CNR-IBIM, Reggio Calabria, Italy;
4Cardiology, University of Catania, Catania, Italy
Introduction and Aims: The clinical diagnosis of atherosclerotic renal
artery stenosis (RAS) remains problematic because its clinical manifesta-
tions are not specific. Fortuitous diagnosis of RAS has become common-
place. The aim of our study was clinical detection and severity determination
of RAS in a high cardiovascular risk population, referred for diagnostic or
therapeutic cardiac catheterization.
Methods: From April to December 2006, all consecutive patients (pts)
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undergoing non-emergent cardiac catheterization at a single institution were
also evaluated for atherosclerotic RAS by renal angiography. Clinical,
laboratory and angiographic data were recorded. Pts enroment will end by
April 2007.
Results: We studied 682 consecutive pts who underwent coronary angiogra-
phy and renal arteriography (age 63±11 yr, M 494 F 188, sCr 1±0.3 mg/dl,
CrCl 87±31 ml/min, Diabetes 36%, Hypertension 87%, Hyperlipidemia
75%). In the aggregate, 49 patients out of 682 (7%) had a significant RAS
(>50%) and 505/682 (74%) had at least 1 coronary vessel involved (1 vessel
in 172 cases, 2 vessels in 168 cases and 3 vessels in 165 cases). On univariate
logistic regression analysis, RAS was significantly associated to the severity
of CAD [n of coronary vessel involved (P<0.001)], history of peripheral
vascular disease (P<0.001), CrCl (P<0.001), serum creatinine (P<0.001),
history of chronic renal insufficiency (P<0.001), hyperlipidemia (P=0.007),
pulse pressure (P=0.008), age (P=0.01), systolic pressure (P=0.03), and
BMI (P=0.05). No significant association was found between renal artery
stenosis and sex, smoking and diabetes. In a multiple logistic regression
model, including all univariate correlates of RAS, serum creatinine [odds ra-
tio (OR) (1 mg/L increase): 6.95, 95% CI: 3.19-15.16, P<0.001], peripheral
vascular disease (OR: 2.75, 95% CI: 1.38-5.49, P=0.004), hyperlipidemia
(OR: 3.00, 95% CI: 1.03-8.77, P=0.04) and number of involved coronary
vessels [OR (1 stenotic vessel increase): 1.39, 95% CI: 1.02-1.89, P=0.04]
maintained an independent association with RAS. In a ROC curve analysis
serum creatinine, peripheral vascular disease, hyperlipidemia and number
of involved coronary vessels jointly produced a ROC curve area of 78.8%
(95% CI: 72.2-85.4%, P<0.001). In this analysis, the contribution of the
number of involved coronary vessels to identify RAS was very low (2.4%).
Accordingly, the estimated probability of significant RAS, adjusted for the
above mentioned significant covariates, associated with 0,1,2,3 CAD-vessels
was 3%, 4%, 6% and 8%, respectively.
Conclusions: In a population at high risk for cardiovascular disease, not
previously suspected of having RAS, the latter is associated with simple and
readily determined clinical and laboratory characteristcs. These data may
facilitate the selection of patients who may have to undergo to diagnostic
renal angiography procedures.
FP165 MORTALITY RISK FOR PATIENTS RECEIVING
HEMODIAFILTRATION VERSUS HEMODIALYSIS:
RESULTS AT TWO YEARS FROM THE RISCAVID STUDY
Vincenzo Panichi, Giovanni Manca Rizza, Sabrina Paoletti,
Emanuela Mantuano, Raffaele Caprioli, Valentina Marchetti, Sara Beati,
Erica Panicucci, Cristina Consani, Alessandro Antonelli, Giacli Donati,
Roberto Bigazzi, Giuliano Barsotti, Paolo Rindi, Mauro Aloisi,
Roberto Palla. RISCAVID Study Group, North-West Tuscany, Italy
Introduction and Aims: RISCAVID (Cardiovascular risk in dialysis) study
is an observational and prospective study of the over 800 patients in
hemodialysis and peritoneal dialysis of the north-west part of Tuscany. This
population is rather peculiar because hemodiafiltration (HDF) is largely
used for renal replacement therapy (44%). Characteristics and outcomes at
two years were compared for patients receiving HDF versus HD.
Methods: The study followed 757 patients stratified into three groups:
standard bicarbonate HD (n.424), and low- (n.205) and high-efficiency HDF
(n.128). At the time of the enrolment demographic, clinical and laboratory
data of the whole population were registered as well as co-morbidity
conditions established by anamnestic and instrumental information. The
population was followed up for 24 months reporting overall mortality,
CV mortality and CV major non fatal events (acute myocardial infarction,
stroke and ictus). Cox proportional hazards regression assessed adjusted
differences in mortality risk.
Results: Patients receiving standard HD had an higher incidence of diabetes
(21.6% vs 16.4% low-eff. HDF vs 16.0% high-eff HDF); patients receiving
low and high-efficiency HDF had significantly longer average duration of
end-stage renal disease (6.5 and 6.3 versus 5.3 years), patients receiving
high-efficiency HDF had significantly more hypertension (60 versus 45%
low-eff HDF).No significant differences were observed in received single-
pool Kt/V (1.40 vs 1.43 vs 1.40). High-efficiency and low-HDF patients had
lower crude mortality rates than standard HD patients. After adjustment,
high-efficiency and low HDF patients had a significant lower mortality risk
than those receiving standard HD (relative risk=0.78, P=0.01).
Conclusions: These observational results at two year from the RISCAVID
study confirm recent findings that HDF may improve patient survival
independently of its higher dialysis dose.
FP166 IDENTIFYING INDIVIDUALS WITH CKD: ARE WE
OVERESTIMATING THE NUMBER?
Laura Clark 1, Gordon Prescott 2, Nicholas Fluck 3, Cairns Smith 2,
William Simpson 4, Alison Macleod 1. 1Medicine and Therapeutics,
University of Aberdeen, Aberdeen, United Kingdom; 2Public Health,
University of Aberdeen, Aberdeen, United Kingdom; 3Renal Medicine, NHS
Grampian, Aberdeen, United Kingdom; 4Clinical Biochemistry, NHS
Grampian, Aberdeen, United Kingdom
Introduction and Aims: Chronic kidney disease (CKD) is becoming
increasingly common in the community as a result of our ageing population
and rising incidence of diabetes. In recognition of this the Quality Outcomes
Framework for CKD has been developed allowing us to identify “at risk”
individuals at a much earlier stage and target management strategies. Despite
this, little is known about the epidemiology and natural history of early
CKD, particularly disease progression, and precisely what impact these
individuals will have on the health service.
We aimed to establish with increased accuracy the prevalence and severity
of CKD in a selected population with at least one abnormal creatinine in
North-East Scotland.
Methods: In a linked study we identified 5751 patients with at least
1 creatinine ≥150umol/l (males) and ≥130umol/l (females) in a 6 month
period using the single laboratory that serves Grampian (pop.500,000). Using
the criteria of 3 abnormal creatinines, at least one month apart, revealed
that 2315 had CKD. 474 had ARF and 88 ACRF using ADQI definition.
1918 patients, however, could not be classified. 1405 of these have been
analysed to date. All available creatinines (median N=27) were converted
to eGFR using the abbreviated MDRD formula. eGFRs were grouped into
3 time periods: Index, Previous and Future. Using median eGFR values
patients were grouped according to their likelihood of having CKD. The
breakdown of groups are as follows: Unlikely n=80 (5%), Uncertain=245
(17%), Probable n=933 (66%), insufficient data n=147(10%). The presence
of markers of kidney damage, co-morbidities and outcomes were identified
from case note review.
Results: The median age was 78 and 80 for males and females respectively.
Median eGFR was 33.4 for females and 38.7 for males. Those in the “at
risk” group were initially staged according to their index eGFR. Markers
of kidney damage determined from case note review allowed a further 61
patients to be staged (994 in total). Of these, 82% are in Stage 3, 17.7%
Stage 4 and 0.3% in Stage 5. Hypertension and ischaemic heart disease
were the most common co-morbidities. Mortality in Stage 3 was 45% at
30-36 months. Median survival from time of index was 1.4 years for Stage
4 and 0.4 years for Stage 5. 131 patients in the “at risk” group without
markers were classed as having no definite evidence of CKD (5% of 1405).
The remaining 336 patients had insufficient data for classification (25% of
1405).
Conclusions: The majority of patients with at least one elevated creatinine
(70%) in this study have evidence of CKD. This predominantly elderly
population if referred to the renal services are likely to utilise a significant
proportion of our health care resources. On the other hand a substantial
minority (30%) have no conclusive evidence of CKD. These patients may
have been included in other prevalence studies thus overestimating the
prevalence of CKD.
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Introduction and Aims: Chronic kidney disease is a non thyroideal illness,
and it has been recently suggested that low levels of free triiodothyronine
(fT3) could be associated with pathological conditions and maladaptation
leading to decreased survival rather than a sign of physiological adaptation
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to energy shortage. In the present study, we explore and compare the
association of decreased thyroid hormone levels (total and free forms) with
inflammation, wasting and survival in patients with end-stage renal disease
(ESRD).
Methods: This is a post hoc, cross-sectional study including 210 ESRD
stage 5 patients close to the start of dialysis therapy, with a follow-up of up
to 60 months. Biochemical measurements of total and free forms of thyroid
hormones, s-albumin, hs-CRP, plasma interleukin (IL)-6, soluble vascular
adhesion molecule-1 (sVCAM-1), insulin-like growth factor 1 (IGF-1) and
8-hydroxy-2’-deoxyguanosine (8-OHdG) were performed.
Results: Multivariate analysis according to receiver operating characteristic
(ROC) curves, showed that among the hormones studied (total and free
forms), mortality was best predicted by total triiodothyronine (T3). When
using the cut-off levels derived from ROC, low T3 levels were associated
with increased inflammation (higher concentration of hs-CRP, IL-6 and
sVCAM-1), increased oxidative stress (higher concentration of 8-OHdG)
and wasting (lower concentration of s-albumin and IGF-1). Finally, low T3
was associated with worse all-cause (Likelihood ratio= 35.9; p<0.0001)
and cardiovascular mortality (Likelihood ratio= 37.6; p<0.0001) after
adjustment for age, gender, presence of diabetes mellitus and inflammation.
Conclusions: This study shows that low thyroid hormone levels are
associated to increased inflammation, wasting and oxidative stress markers
in ESRD patients. This study is also able to compare and propose for the
first time, T3 levels as a more sensitive prognostic factor than fT3 of not
only all-cause but also CVD mortality in ESRD patients. Altogether, the
present study supports the hypothesis that thyroid dysfunction is implicated
in the high mortality risk of the ESRD population.
Supported by an ERA-EDTA grant.
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Introduction and Aims: Stroke represents an entity of major clinical and
epidemiological importance with regard to cardiovascular complications in
patients (p) with chronic kidney disease (CKD).
Methods: The aim of the study was to evaluate retrospectively the incidence
of ischaemic stroke in pre-dialysis CKD p within a 5-year follow-up period
and to assess potentially conducive factors. A group A of 180 p with
CKD and ischaemic stroke recorded out of 2465 p with CKD [males-
100p (55.6%), females- 80p (44.4%), mean age- 65.64±10.92 years] and
a gender- and age- matched group B of 175 CKD p without stroke
[males-116p (66.3%), females- 59p (33.7%), mean age- 64.13±9.75 years]
were assessed concerning classic and non-classic risk factors for stroke,
prevalence of stroke- according to the type and stages of CKD, and
predictors for developing stroke. Also a gender- and age- matched normal
controls group (C) was assessed with regard to the same parameters. A
subgroup of 31 p out of the 180 p with CKD + stroke, underwent extracranial
and transcranial Doppler ultrasound in order to assess the resistance index
(RI) in the internal carotid arteries (ICAS) and the middle cerebral arteries
(MCAS). The RI was correlated with the risk factors proved as significant.
Results: The incidence of ischaemic stroke was 7.35% and of recurrent
stroke recorded in CKD p (group A) was 3.24%. Risk factors for stroke
were serum creatinine (OR.=2.20, P=0.0001), glomerular filtration rate
(GFR) (OR.=0.98, P=0.001), proteinuria (OR.=1.74, P=0.031), C-reactive
protein (CRP) (OR.=1.90, P=0.006), fibrinogen (F) (OR.=1.84, P=0.005),
haemoglobin (OR.=1.68, P=0.041). The prevalence of stroke in relationship
with the stages of CKD: stage 1- 1.1%, stage 2- 22.8% (OR.=1.11), stage 3-
32.8% (OR.=1.30), stage 4- 24.4% (OR.=2.27), stage 5- 18.9% (OR.=2.68)
Predictors for incident and/or for recurrent ischaemic stroke: proteinuria
(OR.1.71, P=0.036), CRP (OR.=1.68, P=0.001), F (OR.=1.43, P=0.043),
GFR (OR.=1.79, P=0.016). The RI correlated significantly in the ICAS
with F (r=0.188, P<0.0001), CRP (r= 0.188, P<0.0001), haemoglobin (r=
-0.45, P<0.0001); in the MCAS fibrinogen (r= 0.1126, P<0.0001), CRP (r=
0.112, P<0.0001), haemoglobin (r= -0.65, p<0.0001), proteinuria (r= 0.21,
P<0.001).
Conclusions: The incidence of ischaemic stroke is high in pre-dialysis CKD
p. The prevalence of stroke is significant even in the early stages of CKD.
Markers of inflammation, proteinuria, haemoglobin, and the level of renal
function were the most significant risk factors for the occurrence/recurrence
of stroke and for cerebral vessels remodelling.
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Introduction and Aims: The aim of this study was to evaluate the effects of
decreased GFR on post op prognosis of patients undergoing general surgery
interventions.
Methods: We investigated 942 randomly assigned patients to this study
(442 male, 500 female, average age 55.68±16.31 years) needing general
surgery intervention. History for previous renal disease (renal function
investigations) for hypertension (HT) and for diabetes mellitus (DM) was
investigated. There have been followed up: blood pressure, hemoglobin,
fasting blood glucose, urine output, serum creatinine, GFR (MDRD 4),
criteria for sepsis and the survival of the patients. Data have been processed
using the R Package statistical software. The t-test and the Fisher exact test
were used for two-group comparisons and multiple regression analysis to
evaluate influence of biological data on post op outcome.
Results: Patients have been divided into two groups: group 1- pre op GFR
<60 ml/min/1,73m2, 24.73% of the cases (average GFR = 44.43±13.06
ml/min/1.73m2) and group 2 - pre op GFR >60 ml/min/1,73m2, 75.27% of
the cases (average GFR 93.71±33.74 ml/min/1.73m2. In group 1 patients
presented significantly higher average age (65.48±11.36 vs. 52.47±16.41
years – p<0.001) and higher prevalence of DM (52.36% vs. 30.18% -
p=0.0001). Concerning the complications, the prevalence of sepsis and of
ARF (according to RIFLE criteria) was significantly higher in the first
group (9.87% vs. 2.96% - p<0.0001) and (30.04% vs. 3.94% - p<0.0001).
18.02% of the patients died in the post op period in group 1 as compared to
4.79% in group 2 (p<0.0001). The post op outcome was influenced by age
of the patients the presence of ARF, of sepsis of high fasting blood sugar
and low systolic blood pressure and not by the other clinical and biological
data that have been followed up. There was an extremely strong dependency
between ARF and low pre op GFR and we interpret these latter results as a
direct consequence this fact.
Conclusions: Our analysis suggests that even moderate reduction of pre
op GFR in patients undergoing general surgery is a risk factor for the
development ARF and sepsis and a poor post op prognosis predictor.
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Introduction and Aims: In US and North Europe cohorts of CKD patients
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selected from general population, incidence of death is 2 to 50 times greater
than that of ESRD and associated with CKD severity. Whether the same
holds true in tertiary nephrology care is unknown. We evaluated outcome
and determinants of renal death in the Italian TABLE cohort of CKD
patients.
Methods: Large prospective cohort was constituted enrolling all consecutive
patients attending 26 renal clinics during a 6-month period of 2002/03 that
had diagnosis of CKD, GFR<60 ml/min/1.73m2 (no dialysis-no transplant)
and Nephrology care from ≥6 months. Follow up for renal death (all-cause
death, ESRD) ended at 11/30/06. Survival analysis was performed by means
of incidence rates and Cox regression model.
Results: Out of 1353 patients screened, 1269 met selection criteria (stage
3, 4, 5: 596, 504, 169). At baseline age was 66±14 y, males 57%, diabetics
28%, cardiovascular (CV) disease 31%, GFR 30.4±13.8 mL/min/1.73
m2, systolic blood pressure (SBP) 139±18 mmHg, total cholesterol (TC)
199±42 mg/dL, haemoglobin (Hb) 12.5±1.8 g/dL, proteinuria 1.03±1.43
g/day. CEI or ARB were prescribed in 72% of patients, statin in 21% and
epoietin in 13%. During a median follow up of 30 months, 258 patients
reached ESRD while 150 died (72% for CV cause) with incidence rates
of 8.8 versus 5.1/100 pts/yr (Figure). Cox model (hazard ratio and 95%
confidence interval) showed that age (1.02, 1.01-1.02, P=0.001), diabetes
(1.26, 1.00-1.60, P=0.049), CV disease (1.57, 1.24-1.97, P=0.0001), and
proteinuria (1.14, 1.08-1.21, P<0.0001) predicted renal death, while a
protective role was found for GFR (0.93, 0.92-0.94, P<0.0001), Hb (0.92,
0.85-0.98, P=0.015) and statin prescription (0.64, 0.47-0.87, P=0.004).
Gender, SBP, TC, and use of CEI/ARB were not significant.
Conclusions: In CKD patients followed in Italian renal clinics, mortality
is less frequent than ESRD and does not increase with worsening of CKD.
Discrepancy with previous studies may be due to the tertiary care setting
and the lower background Italian population CV mortality. Under these
conditions, renal survival can be improved by larger use of statins and more
intensive treatment of proteinuria and anemia.
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Introduction and Aims: CKD is now a worldwide epidemic, which is
possibly due to the continuous increase in the prevalence of MS. MS has
been shown to be strongly associated with CKD in several cohort studies
from different countries. Incidence of end stage renal disease (ESRD) in
Korea is increasing more than 10% annually, which takes the 11th rank
in the world according to USRDS in 2006. Early detection and treatment
of the risk factors for CKD have a paramount importance to reduce the
incidence of ESRD. To better understand the clinical implication of MS as a
risk factor of CKD and its characteristics which is possibly different in each
countries with different ethnic background and life style, we performed a
cross-sectional study in non-institutionalized Korean civilian using the data
of Korean NHANES in 2001.
Methods: Of 7,918 participants, 5,491 at age between 20 and 79 years
were available for analysis for the prevalence of CKD (defined as dipstick
proteinuria or a reduced GFR less than 60 ml/min per 1.73m2 by MDRD
formula). MS was diagnosed by original NCEP-ATP III criteria (waist
circumference, 102 cm for men and 88 cm for women, NCEP-O) or NCEP-
ATP III with the Asia-Pacific abdominal obesity criteria (90 cm for men, 80
cm for women, NCEP-AP).
Results: Overall, 33.9%, 16.2%, 33.1%, 49.0%, 9.9% and 33.6% of
the participants had elevated blood pressure, high plasma glucose, high
triglyceride, low HDL-cholesterol and abdominal obesity by NCEP-O and
NCEP-AP, respectively. The prevalence of MS was 18.0% by NCEP-O and
25.7% by NECP-AP. CKD was seen in 8.7% of subjects. In subjects with
MS, the prevalence of CKD was higher (18.3 vs. 6.7%, p=0.0001) with a
lower GFR (74.2 vs. 80.1 ml/min/1.73 m2, p<0.0001) compared to subjects
without MS. There was a significant graded increase in the prevalence of
CKD with number of components of MS. The multivariate-adjusted odds
ratio of CKD in subjects with MS compared with subjects without MS was
1.50 (95% CI, 1.19 to 1.90, p<0.0001). Compared with subjects with 0 or
1 components, subjects with 5 components of MS had multivariate-adjusted
odds ratio of 6.58 (CI, 4.07 to 7.74, p=0.001).
Conclusions: Metabolic syndrome is a significant determinant of CKD in
Korean general population. Prevalence of low HDL-cholesterol was higher
compared to studies from the US and Japan with a variable prevalence of
CKD.
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Introduction and Aims: Since 1998, by law, all school children in Korea
must have an annual urinalysis. The first early morning urine specimen
is examined by a simple dipstick method for the detection of proteinuria,
hematuria and sugar. If a urine test is positive, a second test is performed
by pediatric nephrologists. We analyzed the results of clinical data and the
renal biopsy findings of patients detected by school urinalysis screening
from 1998 to 2005.
Methods: We analyzed urinalysis data of 2,100 children referred for
urinary abnormalities by school urinalysis screening. We also investigated
histopathologic findings and diagnosis of 1,300 asymptomatic persistent
and/or proteinuria patients who took renal biopsy.
Results: The male to female ratio was 1.4:1 and the mean age 9.8
years. The chief complaints for renal biopsy were 578 cases (45.3%) of
isolated hematuria, 109 cases (8.5%) of isolated proteinuria and 479 cases
(37.5%) of hematuria combined with proteinuria. In the histopathological
findings, primary glomerular disease was 75.8% which was IgA nephropathy
in 30.1%, mesangial proliferative glomerulonephritis in 27.2%. Systemic
disease was 11.4% which was Henoch-Schonlein nephritis in 10.4%, and
lupus nephritis in 0.8%. Alport syndrome showed 1.2% as a hereditary
disease.
Conclusions: Early detection through school urinalysis screening and
confirm diagnosis by renal biopsy seem to be helpful for assessment of
prognosis and intervention of disease progression.
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Introduction and Aims: The number of patients receiving renal replacement
therapy in the UK is rising rapidly, costing over 2% of the total NHS
budget[1]. The Renal Association have published referral guidelines[2] for
CKD re-emphasising the importance of assessing patients with progressive
CKD at Nephrology outpatients.
In the light of current guidelines our aim was to investigate if the assessment
and referral of patients is appropriate based on the progressive risk of CKD.
Methods: In Northern Ireland 2,892,340 creatinine samples from 1st Jan
2001 - 31st Dec 2002 were extracted from regional laboratories. Merging
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these to an enriched General Practice dataset produced a cohort of 75,434
subjects containing 307,663 results. To capture progression over the two-
year period, a three-point assessment was devised. Progression and periods
of regression were characterised by the gradients A and B. A cut-off
level (eGFR 60mls/min) was additionally used to categorise the change in
patient’s eGFR. Progression was also categorised as stable (<1mls/min/yr),
slow (1-5mls/min/yr) and rapid (>5mls/min/yr).
Results: 56,356 (74.7%) subjects had “all eGFR results” >60 mls/min
throughout the entire period, 11,249 (14.9%) had “all eGFR results”
<60 mls/min and 5017 (6.7%) had a minimum eGFR measured below
60mls/min and yet subsequently had a value measured above 60mls/min. In
total, 1,167 were known to Nephrology services. Of these, 341 (29.2%) had
an eGFR>60mls/min over the two year period. Importantly 2,699 (3.6%)
subjects unknown to nephrology demonstrated a rapid decline from stages
1 or 2 CKD to stage 3 or worse.
Conclusions: Progression of CKD is often taught to be linear; this data
indicates that alternative patterns of progression occur in the natural history
of CKD, including improvement in function. Significant numbers of subjects
attending Nephrology services have no evidence of progressive decline in
eGFR whilst the vast majority with CKD remain unseen. Although some
of these patients may have important reasons for attending Nephrology
services, this may be to the detriment of those with more progressive CKD.
References: 1. Roderick, P., Davies, R., Jones, C., Feest, T., Smith, S.,
Farrington, K., Simulation Model of Renal Replacement Therapy: Predicting
Future Demand in England, Nephrol Dial Transplant, 2004; 19(3): 692-701.
2. The Renal Association, UK CKD eGuide, http://www.renal.org.html.
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Introduction and Aims: The reported incidence and sequelae of Hepatitis
C varies significantly internationally and extra-hepatic manifestations of
the disease are common. However, despite the well recognised association
between hepatitis C and glomerulonephritis, the prevalence of renal disease
in this population has not been studied. The purpose of this prospective
study was to determine the prevalence of and risk factors for renal disease
in a Northern European population attending a specialist Hepatitis C clinic.
Methods: All patients attending the specialist hepatitis C clinic during
a 3 month period provided urine and blood samples for renal and liver
function, cryoglobulins, complement, anti-nuclear factor, rheumatoid factor
and immunoglobulins. Renal disease was defined by the presence of
significant proteinuria (>300mg/24hrs), abnormal urinalysis (x3) and/or a
raised serum creatinine (>110mmol/l).
Results: 72 patients (41 male) were included in the study. 59 were HCV
PCR positive and 13 were currently PCR negative. 46 patients had a history
of intravenous drug use, 18 had received infected anti-D immunoglobulin
and 8 were sporadic cases. Mean age was 40.9±10.9 years. 65% of patients
were genotype 1 and 35% were genotype 3. Mean duration of infection was
13.1±9.5 years. 33% were ANF positive and 47% were RF positive. None
of the patients had a history of diabetes mellitus or hypertension.
8 patients (11%) had evidence of renal disease. 7 patients had proteinuria
and 1 had an abnormal urinalysis. All 8 patients were PCR positive. There
was no difference in age, gender, duration of infection or aetiology between
those with and without renal disease. There was a trend towards increased
inflammation and fibrosis in the liver biopsies of those with renal disease.
Patients with renal disease were more likely to have cryoglobulinaemia
(63% v 22%, p=0.01). Serum creatinine was within the normal range in all
but one patient.
Cryoglobulins were present in 27%. None of the PCR negative participants
had cryoglobulinaemia. There was also no difference in age, gender, duration
of infection or aetiology between those with and without cryoglobulins.
Cryoglobulinaemic patients were significantly more likely to be rheumatoid
factor positive (76 v 35%, p=0.008), had higher ALT levels (93 v 50,
p=0.02), lower C4 (0.21 v 0.24, p=0.05) and higher IgG levels (16.5 v 13.7,
(p=0.003).
Conclusions: As far as we are aware, this is the first prospective study
to examine the incidence of renal disease in a population of patients with
hepatitis C. Overall, 11% of the patients in this study had evidence of
renal disease and 27% had cryoglobulinaemia. This represents a higher
prevalence of renal disease in those with hepatitis C than in the general
population. We suggest that all patients with hepatitis C, particularly those
with cryoglobulinaemia, should be screened for renal disease as early
recognition may allow appropriate treatment and possibly reduce future
complications. Further studies are required to confirm these findings.
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PRE-DIALYSIS PATIENTS (OVIDS-CKD)
Naohiko Fujii 1, Takayuki Hamano 2, Satoshi Mikami 2,
Yasuyuki Nagasawa 2, Yoshitaka Isaka 2, Takahito Ito 2, Enyu Imai 2.
1Nephrology, Hyogo Prefectural Hosipital Nishinomiya, Nishinomiya,
Hyogo, Japan; 2Nephrology, Osaka University Graduate School of
Medicine, Suita, Osaka, Japan
Introduction and Aims: We have reported the importance of gender differ-
ence in CKD-MBD among hemodialysis patients. CKD-MBD is character-
ized by three abnormalities; laboratory abnormalities, bone abnormalities,
and calcification of vasculature. Male gender is associated with the severer
calcification both in hemodialysis and pre-dialysis patients. But little is
known about the gender difference in pre-dialysis CKD patients. Our aim is
to elucidate the effect of gender on laboratory and bone abnormalities.
Methods: We conducted a cross-sectional observational study in CKD
patients (OVIDS-CKD; Osaka Vitamin D Study in CKD), who had not
received or were not receiving glucocorticoid, bisphosphonates, or active
vitamin D. Pre-menopausal females were excluded. Whole PTH (wPTH),
bone specific alkaline phosphatase (BSAP), adjusted calcium (Ca), phospho-
rus (P), 25-hydroxyvitamin D (25-OHD), and estradiol (E2) were measured.
We studied the interaction of gender with the relationship between labora-
tory parameters and estimated glomerular filtration rate (eGFR). We also
measured bone mineral density (BMD) in lumbar spine and femoral neck
by dual X-ray absorptiometry. Multiple linear regression analysis for BMD
T-score was performed to determine the significant contributors.
Results: We enrolled 249 patients (186 males, mean age 60.7 years,
eGFR 45.8 23.2 mL/min/1.73m2). P was significantly higher in female, but
no difference was observed in Ca between genders. E2, which elevated
with the reduction of eGFR in both sexes, was significantly higher in
male throughout CKD stages. Whole PTH increased as renal function
declined without significant difference between genders. However, BSAP
was statistically higher in female. Thus, BSAP/wPTH, which denotes
skeletal sensitivity to PTH, was significantly higher in female at eGFR
≥30. But at the lower eGFR, there was no difference between genders
(Fig. 1). Multiple linear regression analyses revealed that the significant
positive contributors to higher lumbar T-score were E2, BMI, and 25-OHD,
whereas in femoral neck 25-OHD, E2, BMI, and eGFR were the positive
contributors. BSAP was negatively associated with both lumbar and femoral
neck T-scores.
Fig. 1
Conclusions: Females seemed to have higher sensitivity of the bone to
PTH than males at eGFR ≥30, although the effect of uremia might override
the gender effect at eGFR <30. The higher E2 levels in males and the
positive correlations between E2 and BMD implied protective effect of E2
on bone metabolism. We should pay attention to gender difference in the
management of CKD-MBD in pre-dialysis patients.
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Introduction and Aims: The aim of this study was to establish clinical and
laboratory characteristics of the population living in the Croatian region of
endemic nephropathy (EN).
Methods: This study included 738 individuals from EN villages (307 male
(M), 431 female (F)), and 120 subjects from a control village (K) (50 M,
70 F). No differences in the distribution of gender and age were observed
between EN and K (p<0.01). Following administration of a detailed
questionnaire and clinical examination, investigators obtained blood and
urine samples from the subjects. The population was classified according
to WHO criteria as diseased (D), suspect (S), at risk (R) and others (O).
The following definitions were used: microalbuminuria (MA) > 30 mg/l;
alpha-1-microalbuminuria (alpha-1) >20 mg/l, hypertension, BP > 140/90
mmHg and/or antihypertensive drug therapy; and anemia (AN) as Hb < 120
g/l in M and <113 g/l in F. Renal disease (RD) was classified according to
NKF classification.
Results: The frequency of the WHO categories in this group was: D=1.4%
(M, 1.73% vs. F, 1.34%, respectively), S=5.6% (M, 7.79% vs. F, 4.83%). If
we analyze only the portion of population who resided >20 years in an EN
village, then the incidence of D is 1.8% and of S is 6.8%. In the subgroup of
persons living in EN villages < 10 years, there was none in the D group and
only 2% were in the S category. In the EN villages, we found an increased
MA frequency compared with K (20.0% vs. 9.8% M, respectively; 16.6% vs.
9.37% F, respectively), as well as an increased frequency of alpha-1 (21.73%
vs. 13.72% M, respectively; F 9.48% vs. 4.54%, respectively). No similar
differences were observed between subgroup O and K. The prevalence of
hypertension was slightly lower in EN villages than in K (51.75% vs. 58.9%;
M 54.07% vs. 57.1%; F 51.97% vs. 58.46%, respectively). There were no
differences in the frequency of RD stages > 2 (by NKF classifications) or
in anemia between EN and K. The duration of residence in EN villages
was significantly correlated to MA, alpha-1 and serum creatinine, but was
not significant for those living < 20 years in EN area and in residents. A
significant correlation was observed between years living in an EN area and
the presence of MA, alpha-1 and serum creatinine even in persons in WHO
categories R and O.
Conclusions: The incidence of D and S in this group has remained the
same as before. The duration of residence in the endemic area affects
EN prevalence. The two village populations differed in MA, alpha-1, and
hypertension frequency but not in anemia and renal disease stage >2. The
known significant association between early renal impairment in persons
classified as R and O living in EN villages, indicates that new diagnoses of
S and D will be registered in the next several years regardless of whether
the causative agent is still present or active.
FP178 PREDICTORS OF GLOMERULAR FILTRATION RATE IN
CONGESTIVE HEART FAILURE – THE NORWEGIAN
EXPERIENCE
Bard Waldum 1, Arne Westheim 2, Morten Grundtvig 2 , Lars Gullestad 2,
Torstein Hole 2, Ingrid Os 1. 1Department of Nephrology, Ulleval University
Hospital, Oslo, Norway; 2Department of Cardiology, Ulleval University
Hospital, Oslo, Norway
Introduction and Aims: Renal dysfunction is common in patients with
congestive heart failure (CHF) and is associated with an adverse prognosis.
The aim of this study was to determine predictors of glomerular filtration
rate (GFR) in a Norwegian cohort with congestive heart failure.
Methods: The registry contains data from 26 heart failure out-patient
clinics at regional hospitals. Patients with heart failure NYHA class I-IV
were consecutively included at the first contact. For this analysis only
patients with systolic dysfunction with ejection fraction (EF) < 45% were
included, and baseline data from 2665 patients (age 69.3±11.9 years,
25.6% females) with CHF (NYHA class I: 4.5%, II: 41.9%, IIIA: 39.8%,
IIIB: 12.3%, IV: 1.6%) were used. GFR was determined with the sMDRD
formula, and classified accordingly in stages 1-5 of chronic kidney disease
(CKD). In multiple regression analysis with GFR as the dependent variable,
age, sex, ejection fraction (EF), NYHA class, systolic blood pressure (SBP),
use of ACE inhibitor/ARB and body mass index (BMI) were entered as
independent variables.
Results: Mean EF was 29±8% in this cohort. Average GFR was 65.4±23.1
ml/min. The prevalence of GFR < 60 ml/min was 44.7%, 13.7% had
CKD stage 1, 43.1% stage 2, 37.8% stage 3, 4.7% stage 4, 0.6% had
CKD stage 5. The use of ACE inhibitors (79%) or angiotensin II receptor
antagonist ARB (27%) was prevalent, and close to 20% used combination
of the two drugs. 14% used neither ACE inhibitor or ARB. Multiple
regression analysis revealed that all entered variables except EF (p=0.157)
were independently and significantly related to GFR, age (p<0.001), gender
(p<0.001), SBP (p<0.001), NYHA class (p<0.001), BMI (p<0.001), use
of ACE inhibitor/ARB (p=0.024). Among subjects below 60 years only
age came out as an independent predictor (p<0.001), while gender did not
reach statistical significance (p=0.09). While in subjects > 60 years of age
(n=1792), age and gender remained independent predictors as did BMI,
NYHA class and SBP while EF and use of ACE inhibitors and/or ARB
did not reach statistical significance as independent predictors (p=0.053 and
0.082 respectively).
Conclusions: In this population with systolic dysfunction and CHF and
with EF < 45%, renal dysfunction was prevalent with 44% had GFR below
60 ml/min. A total of 86% used ACE inhibitors and/or ARB, and this was
associated with higher GFR. Age and gender were the strongest independent
predictors of GFR. In this cohort, EF was not a independent predictor in
contrast to NYHA class, SBP and BMI.
FP179 CHRONIC KIDNEY DISEASE IN PRIMARY CARE
SETTINGS IN SPAIN. THE EROCAP STUDY
Alberto Martinez-Castelao, Aleix Cases, Angel L.M. De Francisco, Juan
Jose De La Cruz, Mariano De La Afiguera, Isabel Egocheaga, Jose
Luis Gorriz, Jose Luis Llisterri, Rafael Marin. Nephrology, H.U.Bellvitge,
Hospitalet, Barcelona, Spain; Nephrology, H Clínic, Barcelona, Spain;
Nephrology, HU Marqués Valdecilla, Santander, Cantabria, Spain; Med
Preventiva, Faculty of Medicine, Madrid, Spain; Primary Care, CAP La
Mina, Barcelona, Spain; Primary Care, CAP Isla de Oza, Madrid, Spain;
Nephrology, HU Dr Peset, Valencia, Spain; Primary Care, CAP Alacues,
Valencia, Spain; Nephrology, HUCA, Oviedo, Spain
Introduction and Aims: This cross-sectional, multicenter study investigated
the prevalence of chronic kidney disease (CKD) and associated disorders, in
an adult population sample (>18 years old) attending Primary Care services
in Spain.
Methods: Estimated glomerular filtration rate (Modification of Diet in Renal
Disease equation) was used for analysis of CKD prevalence according to
NFK-KDOQI stages.
Results: Serum creatinine and other laboratory parameters, blood pressure
and medical history of cardiovascular risk factors or disease (hypertension,
dislypidemia, diabetes, congestive heart failure, coronary artery disesase,
stroke or peripheral vascular disease) were obtained in 7202 patients
attending Primary Care Centers. 47.3% were males, mean age 60,6±14,3
years, BMI 28.2±5.3 kg/m2, 27,6% were overweight (27-30 kg/m2) and
32,1% obese (BMI ≥30kg/m2), The prevalence of cardiovascular (CV) risks
factors (RF) were: absence in 17,3%, one factor 26,9% two 31,2%, and
23,6% presented ≥3. The frequency of CVRF was: hypertension (66,7%),
dyslipidemia (48%) and diabetes (31,5%). Congestive heart failure, coronary
artery disease, stroke or peripheral vascular disease prevalence was lower
than 10%.
The prevalence of eGFR <60 ml/min/1.73 m2 was: stage 3 (GFR 60-30
ml/min) 19,7%; stage 4 (GFR 30-15 ml/min) 1,2%; stage 5 no dialysis (GFR
<15 ml/min) 0,4%. This prevalence increased with age in both sexes and
33,7% of patients attending Primary Care services over 70 years presented
an eGFR < 60 ml/min. Of the total number of patients having an eGFR<
60 ml/min 37.3% had serum creatinine levels within the normal range.
Conclusions: This study documents the substantial prevalence of signif-
icantly abnormal renal function among patients attended at the Primary
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Care level. Early identification and appropriate nephrological management
of these patients with renal disease is an important opportunity for an
adequate prescription of drugs that interfere with renal function, to delay
the progression of renal disease and modify CVRF.
FP180 CAN A PHYSIOTHERAPY-LED OUTPATIENT RENAL
REHABILITATION PROGRAMME ACHIEVE SIGNIFICANT
IMPROVEMENTS IN EXERCISE CAPACITY, FUNCTIONAL
ABILITY AND QUALITY OF LIFE IN PATIENTS WITH
CHRONIC KIDNEY DISEASE (CKD)
Sharlene Cook, Herolin Hopwood. Physiotherapy, King’s College Hospital,
London, United Kingdom
Introduction and Aims: The majority of patients can exercise during
all stages of chronic kidney disease (CKD) but exercise is still not
routinely advocated in renal disease compared with best practice in other
diseased populations such as cardiac and pulmonary disease. The first
U.K physiotherapy-led Renal Rehabilitation Programme, comprising of 12
weeks of twice-weekly supervised exercise and education sessions, and
once-weekly specific home exercises, was initiated to determine whether
patients with CKD could achieve significant improvements in exercise
capacity and functional ability.
Methods: 30 patients (13M;17F) have completed 12 weeks in the pro-
gramme and have been monitored for exercise performance tests at baseline
and 12 weeks. Exercise performance tests included the Incremental Shut-
tle Walk Test (ISWT), sit to stand 60 (STS60), timed up and go 3m
(TUAG3m), stair climb/descent (SCD), Duke’s activity status index (DASI)
and the Hospital Anxiety Depression assessment (HAD).
Results: Student’s paired t-test analyses were performed to assess dif-
ferences between baseline and 12 week data. ISWT improved by 54%
(p<0.001), STS60 by 40% (p<0.001), TUAG3m by 28% (p<0.001), SCD
by 33% (p<0.001), DASI by 67% (p<0.001), HAD anxiety score by 11%
(p<0.001) and HAD depression score by 27% (p<0.001) after 12 weeks.
Conclusions: Increased fitness and muscle strength makes activities of
daily living easier as is demonstrated by the significant improvements in the
DASI score, and enables some people to increase return to activities that
they enjoy such as walking or playing sport. Preliminary experience from
this renal rehabilitation programme combining 12 weeks of exercise and
education suggests that significant improvements in exercise capacity and
physical functioning can be achieved in CKD patients with a supervised
outpatient exercise programme.
FP181 SHORT TERM SURVIVAL IN CHRONIC KIDNEY DISEASE
PATIENTS WITH STROKE
Adalbert Schiller 1, Nicoleta Genoveva Mardare 2, Adrian Covic 2,
Ligia Petrica 1, Maxim Petrica 3, Adelina Mihaescu 2, Norica Posta 2.
1Nephrology Department, Emergency Clinical Hospital, Timisoara,
Romania; 2Dialysis and Transplantation Center, “C.I. Parhon” University
Hospital, Iasi, Romania; 3Neurology Department, Emergency Clinical
Hospital, Timisoara, Romania
Introduction and Aims: Chronic kidney disease (CKD) occurs commonly
in patients with vascular disease. In addition, CKD is a risk factor for
the development and progression of vascular disease. Recent studies have
confirmed that even early CKD constitutes a significant risk factor for
non-fatal cardiovascular events and death. Our aim was first to investigate in
a large series of consecutive patients hospitalized for stroke the prevalence
of CKD and second to assess determinants short-term survival, in this high
risk population with associated cardiovascular disease and CKD.
Methods: Study population: 1090 consecutive subjects (mean age was
66.6±11.5 years, 49.3% males) admitted for confirmed (by CT scan)
ischemic or hemorrhagic stroke. Collected data: associated comorbidities,
cause of CKD, biochemical parameters at admission including serum
creatinine, development of acute renal failure during hospitalization (as
defined by RIFLE criteria) and 30 days survival.
Results: The demographic characteristics of the study group are presented
in Table 1. There were no significant differences in biochemical parameters
between the four CKD subgroups, at baseline. In this cohort, 187 patients
died during the first 30 days after stroke.
The deceased patients were older, had higher serum creatinine at admission
and higher serum glucose (p<0.05). The mean survival in CKD stage 4 and
5 patients was 16±2 days, significantly worse than for other CKD stages
(log rank test = 0.0001). Cox Regression model show age (RR = 1,037, 95%
CI = 1.021-1.054), serum glucose (RR = 1.005, 95% CI = 1.002-1.007),
CKD stage4 and 5 (RR = 2.563, 95% CI = 1.489-4.409), presence of chronic
heart failure (RR = 0.418, 95% CI = 0.3-0.583), type of stroke (RR = 2.59,
95% CI = 1,87-3.67) and development of acute renal failure (RR = 0.326,
95% CI = 0.22-0.483) to be predictors of 30 day survival.
Table 1. Demographic characteristics of the study group
N = 1090 CKD 1 CKD 2 CKD 3 CKD 4-5
N = 167 N = 551 N = 328 N = 44
Age (year) 59.9±12.4 64.9±11.3 70.2±9.4 71.5±10.6*
Males (%) 74.2% 52.8% 32.9% 31.8%*
Diabetes mellitus (%) 21% 24.5% 35.1% 31.1%*
Acute renal failure (%) 1.1% 4.5% 31.1% 65.9%*
Deaths (%) 15.5% 11.9% 21.9% 52.2%*
Mean survival (day) 26±1 27±1 25±1 16±2**
*p < 0.05 for trend, **p< 0.05 at Kaplan Meier analysis for CKD stage 4-5 vs other
CKD stages
Conclusions: A chronically impaired renal function is frequently encoun-
tered in patients admitted with stroke and has severe impact on short-term
mortality and morbidity.
FP182 CHRONIC KIDNEY DISEASE MINERAL AND BONE
DISORDER (MBD) MANAGEMENT IN CKD STAGE 3-4.
MERENA STUDY
Jose Portolés 1, Jose L. Górriz 2, Alberto Martnez-Castelao 3, Fernando De
Álvaro 4, Jose Luño 5, Aleix Cases 6, Juan Navarro 7. 1Nephrology,
Fundación H. Alcorcón, Madrid, Spain; 2Nephrology, H. Pesset, Valencia,
Spain; 3Nephrology, H. Bellvitge, Barcelona, Spain; 4Nephrology, H. La
Paz, Madrid, Spain; 5Nephrology, H. Gregorio Marañón, Madrid, Spain;
6Nephrology, H. Clínico, Barcelona, Spain; 7Nephrology, Tenerife, Spain
Introduction and Aims: K/DOQI® Guidelines defines the treatment and
the targets for CKD mineral and bone mineral disorder (BMD) management
at every CKD stage. A lot of information concerning BMD on dialysis
patients is now available but very little is known about CKD stages 3 and 4.
AIM: To describe the Guidelines adherence and clinical management of
BMD in Nephrology Outpatient Clinic (NOC) all over the country.
Methods: MERENA is an observational prospective, multicentre study to
describe the global clinical management and three years outcome of CKD
patients in stage 3-4. Nephrologist collected data in a web-based electronic
CRF. We analyse here the basal data of the cohort related to BMD-CKD
treatment and the targets obtained.
Results: (marked as *:p<0.0001;+:p<0,01). 1115 patients from 50 NOCs
were included (CCr:31±10 ml/min, aged: 67±13 y.). We classify patients
in CKD3 and CKD4 using C-G formula and found 49% CKD 3 and 51%
CKD 4 (CCr 23,1±4,2 vs 40,1±7,9 ml/min*). CKD 4 patients presented
with higher serum phosphorus (P) (4,0±0,8 vs3,5±0,6 mg/dl*), CaxP
product (37,2±7,7 vs33,4±6,1 mg2/dl2*) and intact-PTH (173,6±134 vs
125,4±95,6 pg/ml*) than CKD 3 ones. In spite of a higher use of phosphate
binders (29,3 vs 11,3%*) and vitamin D (19,8 vs 10,3%*), CKD 4 patients
shown lower target achievement: I-PTH >300 pg/ml (12,9 vs 4,2%*),
hyperP (15,4 vs 4,2%*) and CaxP product >55 (2,8 vs 0,4%+). Only 17,2%
of CKD 4 patients and 23% of CKD 3 achieve all the K/DOQI- BMD
targets. The relative risk of iPTH>300 pg/ml was 3,29 IC [1,76-6,15] in
CKD 4 vs CKD 3 adjusted by age and treatment. We found no differences
between DM and Non-DM patients.
A majority (68%) of CKD-4 patients with I-PTH >150 pg/ml did not
receive vitamin D (without a contraindication due to Ca or P levels) and
53% of patients that should be under chelant treatment did not receive it.
70% of patients with an I-PTH of 131 pg/ml (31,4% > 150 pg/ml) and a
serum P up to 6,7, didn’t receive phosphate binders nor vit D in spite of 43
months under nephrologist care, but 93% of them received antihypertensive
agents and 20% erythropoietic agents.
Conclusions: We present now large-scale data concerning BMD manage-
ment on CKD 3 and 4. Nephrologists seem to undertreat BMD with poor
Guidelines adherence and results.
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FP183 THE EVALUATION OF EFFECTS OF L-CARNITINE
SUPPLEMENTATION ON PREVENTION OF MUSCULAR
SYMPTOMS IN PATIENTS UNDER CHRONIC
HEMODIALYSIS
Jamshid Roozbeh 1, Hamed Jalaeian 2. 1Dept. of Internal Medicine,
Nephrology, Nemazi Hospital, Shiraz University of Medical Sciences,
Shiraz, Fars, Iran; 2Shiraz Organ Transplant Center, Nemazi Hospital,
Shiraz University of Medical Sciences, Shiraz, Fars, Iran
Introduction and Aims: L-carnitine plays an important role in oxidation
of fatty acids. It is essential in tissues that preferentially use fatty acids
for their energy needs, especially skeletal muscle and myocardium. It is
lost from plasma during hemodialysis and is lower in skeletal muscle of
end-stage renal disease (ESRD) patients undergoing chronic hemodialysis.
The aim of study was to evaluate effects of L-carnitine supplementation on
prevention of muscular symptoms in patients under chronic hemodialysis.
Methods: In a double-blind clinical trial, sixty ESRD patients were assigned
to two groups: Group A consisted of 30 patients who received 500 mg oral
L-carnitine everyday for 8 weeks, and group B received a placebo. At 2,
4, and 8 weeks after the initiation of treatment, subjects were asked about
muscle symptoms (weakness, fatigue, cramps/aches).
Results: 93.2% of subjects of group A had at least some improvement
in muscular symptoms. Five patients (16.6%) reported mild progress,
11 (36.6%) had moderate and 12 (40%) reported marked improvement.
Whereas, only nine subjects (30%) reported some mild improved muscular
symptoms and the rest (70%) did not report any improvement. (p<0.05).
Conclusions: Low-dose L-carnitine supplementation in hemodialysis pa-
tients improves muscular symptoms and their sense of wellbeing by restoring
carnitine tissue levels and washing out cumulative acyl moieties.
FP184 BONE MARROW IRON STORES AND IV IRON
SUPPLEMENTATION IN ANEMIA OF NON-DIALYZED CKD
PATIENTS
Gabriel Mircescu, Simona Stancu, Adrian Zugravu, Ligia Petrescu,
Liliana Garneata, Cristina Capusa, Mircea Coman, Ana Stanciu.
Nephrology, “Carol Davila” Clinical Hospital of Nephrology, Bucharest,
Romania
Introduction and Aims: Iron deficiency is common in anemic CKD non-
dialyzed patients. By it’s correction only, about 1/3 of patients reached
the hemoglobin (Hb) target. Peripheral markers of iron deficiency are not
validated yet and central markers (eg bone marrow iron stores) are seldom
reported.
This study aims to evaluate the relation among the bone marrow iron stores,
peripheral markers of iron deficiency and therapeutic effect of IV iron
sucrose in anemic CKD non-dialyzed patients.
Methods: 70 anemic (Hb≤10.5g/dL) CKD patients EPO and iron-naive
were enrolled [55% men; median age 60 (24-84yrs)]. The main primary
renal diseases were vascular and glomerular nephropathies (43% and
33%); only 11% had diabetic nephropathy. The mean eGFR (MDRD) was
15.7±9.6mL/min (64% CKD stage 5). 40% had CRP<10mg/L.
Hb, central [bone marrow aspiration, Prussian Blue stain, type I and II
syderoblasts (%)] and peripheral [serum iron, serum transferrin saturation
(TS), serum ferritin] parameters of iron status were evaluated at baseline.
The percentual distributions of patients according to bone marrow iron stores
(absent, normal, high) in quartiles of serum iron, TS and serum ferritin were
evaluated. One month after therapy (iron sucrose - VENOFER® - 200mg
IV push in 2-5min, daily for 5 days), Hb and peripheral parameters of iron
status were reassessed.
Results: At baseline, iron stores were absent in 46%, normal in 38%
and increased in 16% of patients. A ferritin level<185ng/mL was more
frequently associated with depleted iron stores(63% of patients vs 28%), as
were iron serum < 62μg/dL(66% vs 26%) and TS< 25%(63.2% vs 25%)
Mean Hb significantly increased after iron therapy irrespective of iron
stores, but the patients with low and normal iron stores had significantly
faster rates (1.13±0.3 and 1.04±0.19g/dL/month) than those with high
ones(0.8±0.4g/dL/month). 36% more patients attained the local target
Hb>10.5g/dL(47% vs 11%; p<0.05); the increase was significant only in
those with low and normal iron stores(46% and 58%) than in those with
high iron stores(1%).
Neither renal function nor inflammation did influence the relation among
central and peripheral markers of iron deficiency or the treatment outcome.
Bone marrow iron stores
A - Absent B - Normal C - Increased
Patients(%) 32(46%) 27(38%) 11(16%)
Baseline
Hb (g/dL, mean±SD) 8.99±1.24 (1) 9.48±0.9 (2) 8.55±0.9
Serum iron (mcg/L)*μ 50 [17-93] (1) 75 [45-156] (2) 78 [37-120] (3)
TS (%, mean±SD) 21.6±7.5 (1) 26.7±8 (2) 31±8.7 (3)
Serum ferritin (mcg/L)* 125 [39-510] (1) 209 [56-450] (2) 357 [113-727] (3)
After iron therapy
Hb (g/dL, mean±SD) 10.09±1.2 10.43±0.9 9.34±0.9
Hb (g/dL, mean±SD) 1.13±0.3 1.04±0.19 (2) 0.80±0.4 (3)
*median, iq range; (1) p<0.05; A vs B; (2) p<0.05; B vs C; (3) p<0.05; A vs C
Conclusions: Although iron stores, ferritin level and TS seem to be useful
indicators of absolute iron deficiency, predicting the increase in Hb after
correction, the therapeutic trial of iron supplementation is worthy in anemic
pre-dialysis CKD patients as even those with repleted iron stores could
respond to IV iron.
FP185 A PROSPECTIVE COHORT STUDY OF SURVIVAL IN
INCIDENT ADULTS WITH END STAGE KIDNEY DISEASE,
RESIDENT IN SOUTH WEST IRELAND
Gemma M. Browne 1,2, William D. Plant 1. 1Department of Renal Medicine,
Cork University Hospital, Cork, Ireland; 2Department of Epidemiology and
Public Health, University College Cork, Cork, Ireland
Introduction and Aims: In the Republic of Ireland there is currently no reg-
istry of end stage kidney disease (ESKD). This study prospectively follows
the cohort resident in counties Cork and Kerry (population 580,356) com-
mencing renal replacement therapy (RRT) from 01.01.2002 to 31.12.2005.
Survival and the factors that predict survival were modelled. UK Renal
Registry data were used for comparison.
Methods: 197 adult subjects commenced RRT. Covariates include: age at
start RRT ESKD aetiology, mode of RRT, initial type of dialysis access
and nephrology review for at least 3 months prior to RRT. Co-morbidity
was measured by Davies index. Serum albumin at commencement of RRT
was recorded. Survival time was from commencement of RRT to 1.05.2006
or death, without censure at transplant. Cox regression was used to model
potential factors influencing survival and to derive crude and adjusted hazard
ratios (HR). Bidirectional stepwise model regression excluded covariates no
longer associated with survival. Crude mortality rate was calculated. 1 year
cohort survival was compared to the UK Renal Registry Report 2004.
Results: The crude mortality rate was 16.2 deaths per 100 person-years
(95% CI 12.5, 21.0). 57 subjects died. Median follow up was 1.6 years
(IQR 0.7, 2.8). Haemodialysis was the first modality in 162 (83%) subjects,
and 34 (17%) commenced RRT with CAPD, with 1 pre-emptive transplant.
Age, ESKD aetiology, mode of RRT and albumin<30g/L had crude effects,
but were no longer associated with survival in the multivariate model.
Univariate & multivariate HR for death
Unadjusted HR p Adjusted HR p
n=196 (95% CI) wald test (95% CI) wald test
Davies Index 0 1.0 1.0
1-2 12.2 (4.3,34.6) <0.001 6.7 (3.2,26.2) 0.001
3-5 25.8 (8.7,76.3) <0.001 9.1 (2.9, 28.5) <0.001
Nephrology Review 0.28 (0.17,0.48) <0.001 0.47 (0.25,0. 9) 0.02
Elective Access 1.0 1.0
Tunnelled Catheter 5.1 (2.3,11.4) <0.001 2.53 (1.1,5.9) 0.03
Temporary Catheter 10.4 (4.1, 26.5) <0.001 3.49 (1.2, 10.1) 0.02
Transplant list 0.04 (0.01, 0.18) <0.001 0.19 (0.3,0.9) 0.04
Unadjusted 1 year survival by age
Age KM survival (%) KM 95%CI
SW Ireland n=129 18-64 87.2% 80.0-92.0
n=68 >65 66.9% 53.3-77.5
n=197 All ages 81% 74.0-86.0
UK Registry n=1,663 18-64 88.9% 87.4-90.4
n=1,806 >65 67.0% 64.9-69.2
n=3,469 All ages 77.6% 76.3-79.0
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Co-morbidity, nephrology review, initial access and selection for transplant
waiting list continue to be associated with survival on multivariate analysis.
Conclusions: In South-West Ireland, factors relating to elective commence-
ment of dialysis (prior nephrology review, permanent initial dialysis access)
result in a survival advantage. Subjects selected for transplant waiting list,
despite adjustment for age and comorbidity have the strongest survival
advantage. 1 year survival is similar to that of the UK Renal Registry.
FP186 ATHEROSCLEROTIC RENOVASCULAR DISEASE (ARVD)
IN A HIGH CARDIOVASCULAR (CV) RISK POPULATION
Carmelita Marcantoni 1, Luca Zanoli 2, Stefania Rastelli 2 ,
Giovanni Tripepi 3, Salvo Virzi 4, Domenico Di Landro 1,
Corrado Tamburino 4, Carmine Zoccali 3, Pietro Castellino 2 . 1Nephrology,
Cannizzaro Hospital, Catania, CT, Italy; 2Internal Medicine and Nephrol,
University of Catania, Catania, CT, Italy; 3CNR-IBIM, Reggio Calabria,
RC, Italy; 4Cardiology, University of Catania, Catania, CT, Italy
Introduction and Aims: ARVD may play a role in the pathophysiology and
progression of cardiac heart failure and chronic renal failure. Few studies
have addressed renal artery stenosis (RAS) prevalence in populations with
high-very high CV risk, such us patients (pts) undergoing diagnostic or
therapeutic cardiac catheterization.
This study was performed to determine the prevalence of ARVD in a cohort
of patients with high CV risk, referred for diagnostic or therapeutic cardiac
catheterization.
Methods: From April 2006, all consecutive pts undergoing cardiac catheter-
ization (acute MI excluded) at a single institution were also evaluated for the
presence of RAS by renal angiography. Clinical, laboratory and angiographic
data were recorded. Pts enrolment will end by April 2007.
Results: Renal arteriography was performed in 967 pts. Angiographically
evident ARVD was present in 252 pts (26.1%), with RAS ≥50% in 62
pts (6.4%) and <50% in 190 pts (19.6%); monolateral in 74.6% of pts.
Demographic data are reported in the table. Coronary artery disease (CAD)
was more severe in pts with significant RAS than in pts without ARVD,
showing a significant higher prevalence of the three vessel disease (43.3%
vs 20.2% P<0.001). All patients with significant RAS had at least a single
vessel-CAD with 73.3% of them with 2- or 3- vessel CAD.
There were no complications related to renal artery disease screening.
Conclusions: The prevalence of renal artery stenosis >50% in an unselected
cohort of pts undergoing cardiac catheterization was significant (6.5%). Our
data support the role of renal arteriography in order to detect clinically silent
ARVD during cardiac catheterization in patients with high CV risk.
Variables No ARVD RAS≥50% P value
No. of Patients 715 62
Age (yrs) 62±10.2 68.1±8.2 <0.001
Male sex, n (%) 522 (73%) 39 (62.9%) NS
sCr (mg/dl) 0.9±0.3 1.2±0.5 <0.001
CrCl ml/min (Cockcroft & Gault) 90.1±30.3 66.4±30.9 < 0.001
Systolic BP (mmHg) 129.2±16.4 134.8±19 <0.05
Diastolic BP (mmHg) 77.5±10.1 76.6±9.9 NS
Antihypert. Drug Mean N° 1.6±1.2 2±1.1 <0.05
Hyperlipidemia (%) 72 92 <0.001
Diabetes (%) 33 44 NS
Smoking (%) 58 48 NS
Hypertension (%) 83 95 <0.05
History of CAD (%) 59 74.1 <0.05
History of Stroke (%) 5 5 NS
History of PVD (%) 10 31 <0.001
History of CRF (%) 3 19 <0.001
Furthermore, some clinical factors (older age, mild impaired renal function,
blood pressure control, hyperlipidemia, coronary and peripheral atheroscle-
rotic vascular disease) seem to be associated with severity of atherosclerotic
renovascular disease.
FP187 HYPERURICEMIA ACTS AS AN INDEPENDENT
PREDICTOR OF POOR GLOMERULAR FILTRATION RATE
IN THE GERIATRIC POPULATION
Hon-yen Wu 1,2, Chih-Kang Chiang 1, Chung-Jen Yen 1, Kuan-Dun Wu 1.
1Department of Internal Medicine, National Taiwan University Hospital,
Taipei, Taiwan; 2Department of Internal Medicine, Far Eastern Memorial
Hospital, Taipei, Taiwan
Introduction and Aims: Uric acid has been considered as a non-traditional
risk factor of cardiovascular disease (CVD). Chronic kidney disease (CKD)
patients have a high risk of CVD-related morbidity and mortality. Epi-
demiological evidences for the significance of hyperuricemia on the risk
for kidney dysfunction is scarce, especially in the geriatric population. We
hope to identify the possible relationship between hyperuricemia and renal
function in the elder population.
Methods: All patients were older than 65 years visiting National Taiwan
University Hospital for elder health examination during Jan. and Dec. 2003.
We applied the Modification of Diet in Renal Disease (MDRD) equation 7
to estimate glomerular filtration rates (GFRs). Sex, age, body height, and
body weight were recorded. All biochemistry data were measured in a single
clinical laboratory. Linear regression model was applied to find factors that
are independently associated with GFRs. Receiver operating characteristic
(ROC) curve idnetify the cut-off values to predict advanced CKD (stage III
to V).
Results: The study enrolled 491 men and 309 women with mean age
(74.5±5.2), mean uric acid (6.2±1.5 mg/dL) and GFRs (87.8±18.5
ml/min/1.73m2). Age, serum uric acid, creatinine and BUN are nega-
tively associated with MDRD-GFRs, but serum albumin and hemoglobin
are associated positively. Stepwise regression identifies seven factors as an
independent predictor for MDRD-GFRs (Table 1). Hyperuricemia acts an
independent predictor for GFRs after adjusting conventional factors influent
renal function. ROC curves identify uric acid greater than 6.75 mg/dL in
men, and 5.95 mg/dL in women were the cut-off value to predict advanced
CKD in the geriatric population (Figure 1).
Table 1. Predictors of glomerular filitration rate (GFR) in geriatric population: multi-
variate linear regression model with stepwise method
Predictive variables Multivariate regression (R2 for p value
Regression full model = 0.615)
coefficients (B) 95% CI for B
Serum creatinine, mg/dl -22.170 -24.632 to -19.708 <0.001
Serum blood urea nitrogen, mg/dl -0.832 -1.006 to -0.659 <0.001
Male, vs. female 7.452 5.548 to 9.355 <0.001
Age, per year-old -0.555 -0.712 to -0.397 <0.001
Serum uric acid, mg/dl -1.657 -2.220 to -1.094 <0.001
Serum albumin, g/dl 6.146 2.854 to 9.437 <0.001
Serum total cholesterol, mg/dl -0.029 -0.054 to -0.004 0.023
Fig. 1. Receiver operating characteristic (ROC) curve analysis of serum uric acid levels
for the prediction of advanced chronic kidney disease (CKD) in geriatric (A) male
population. Cut-off value of serum uric acid ≥6.75 mg/dL; sensitivity, 69.2, specificity,
56.6; and area under curve, 0.713 (95% Confidence interval, 0.609–0.816. (B) Female
population. Cut-off value of serum uric acid ≥5.95 mg/dL, sensitivity, 50.0, specificity,
64.7, and area under curve, 0.671 (95% Confidence Interval, 0.545-0.795).
Conclusions: Hyperuricemia were independently associated with poor
GFRs in the geriatric population. Whether hypouricemic therapy leads
to renal protection in this CKD high risk population deserves further
investigation.
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FP188 CHOICE OF INITIAL MODALITY OF CHRONIC DIALYSIS
TREATMENT AND EFFECT ON SURVIVAL
Anteo Di Napoli 1, Domenico Di Lallo 1, Serena Chicca 1, Salvatore Di
Giulio 2 , for Lazio Dialysis Registry 3 . 1Lazio Dialysis Registry, Agency for
Public Health of Lazio Region, Rome, Italy; 2Nephrology and Dialysis Unit,
San Camillo - Forlanini Hospital, Rome, Italy; 3Lazio Dialysis Region,
Agency for Public Health of Lazio Region, Rome, Italy
Introduction and Aims: Several studies investigated the factors related to
the chronic dialysis (CD) modality choice and the outcomes of patients
starting with hemodialysis (HD), hemodiafiltration (HDF) and peritoneal
dialysis (DP). However, few studies were performed using data derived
from an area-based registry. The aim of the study is to evaluate the factors
influencing the CD modality choice and the effect of first type of dialysis
on patients’ survival.
Methods: Prospective cohort study of 8122 undergoing chronic dialysis
patients notified to Lazio Dialysis Registry (Italy) from 1-1-1995 to 31-
12-2005. We performed a multinomial logistic regression to estimate
determinants of choice of initial modality of CD, and a multiple Cox model
to estimate mortality hazard ratios (HR).
Results: We observed 90.4% HD, 2.2% HDF, 7.3% DP as first dialysis
modality; an older mean age in HD patients (64.2, SD 15.8), compared
to HDF (55.6, SD 17.4) and DP (58.5, SD 18.6). A higher probability
of initiation with HD compared both HDF and DP was found for: age
>64 years (OR 3.50; 95%CI 2.40-5.11and OR 1.52; 95%CI 1.25-1.85),
cancer (OR 2.59; 95%CI 0.94-7.13 and OR 1.88; 95%CI 1.17-3.04). A
higher probability of initiation with HD compared to DP was found for
vasculopathy (OR 1.40; 95%CI 1.04-1.88) and compared to HDF for women
(OR 1.68; 95%CI 1.17-2.43). A higher probability of initiation with HDF
compared to HD was found for coronary heart disease (OR 1.54; 95%CI
1.02-2.33) and congestive heart failure (OR 1.71; 95%CI 1.03-2.84) and
compared to DP for HCV positive subjects (OR 2.16; 95%CI 1.14-4.09).
A higher probability of initiation with DP compared both HD and HDF
was found for patients with self-sufficiency (OR 2.12; 95%CI 1.67-2.69
and OR 2.09; 95%CI 1.33-3.29). A higher probability of initiation with DP
compared to HD was found for coronary heart disease (OR 1.36; 95%CI
1.06-1.73) and hypertension (OR 1.47; 95%CI 1.22-1.76) and compared to
HDF for women (OR 1.85; 95%CI 1.24-2.77) and age >64 years (OR 2.30;
95%CI 1.52-3.49). No difference in survival was found between patients
starting with HD or HDF (HR 1.04; 95%CI 0.78-1.38) and DP (HR 1.10;
95%CI 0.94-1.29).
Conclusions: Our findings seems to suggest that evaluation of clinical
condition and patient’s autonomy are determinants of choice of initial
modality of CD treatment. However, as we confirm no association between
long-term survival and first dialysis modality, the preference of the patients
should have more relevance in the choice of first type of CD treatment.
FP189 DOES AREA SOCIOECONOMIC STATUS (SES) PREDICT
INCIDENCE AND RATE OF PROGRESSION OF CHRONIC
KIDNEY DISEASE (CKD): A PILOT STUDY BASED ON A
CLINIC POPULATION
Mohammad Hossain, E.C. Goyder, Jan Rigby, A.M. El Nahas. Department
of Nephrology, Sheffield Kidney Institute, The University of Sheffield,
Sheffield, South Yourkshire, United Kingdom; Department of Public Health,
ScHARR, The University of Sheffield, Sheffield, South Yorkshire, United
Kingdom; Department of Geography, The University of Sheffield, Sheffield,
South Yorkshire, United Kingdom; Department of Nephrology, Sheffield
Kidney Institute, The University of Sheffield, Sheffield, South Yorkshire,
United Kingdom
Introduction and Aims: Low socioeconomic status is associated with
several chronic diseases, but evidence relating to CKD is scant. A few
studies suggest that SES is an independent risk factor of progression
of CKD and clinical outcomes. This pilot study attempts to explore the
association of SES levels attributed to a geographical area (super output
area) and CKD.
Methods: A study population of 458 diagnosed CKD patients was collected
as a systematic sample (1 in 8 cases) from the total number of CKD patients
being followed-up in the Sheffield Kidney Institute. Area level SES was
classified using the Index of Multiple Deprivation 2004 (IMD 2004) which
includes measures of income, employment, health and disability, education,
skills and training, barriers to housing and services, living environment and
crime. We also analysed the data from a subgroup of 104 patients with CKD
(1 in 4 cases of 458 total populations) at baseline clinical and biochemical
presentation of CKD and its progression rate.
Results: Demographic characteristics. Of this sample, 59% lived in the
most deprived areas (fifth quintile by IMD), in whom 87% were white
compared to 13% non-white (8% Asians,2% Caribbean,3% Somali). There
was a higher number of males with CKD (61%). Overall 16% of patients
were aged over 80years, 48% aged 61-80, 12% aged 41-60 and 23% aged
20-40. The distribution across deprivation quintiles was similar for all age
groups, except for the 40-60 age group who were slightly more likely to
be living in the most deprived areas. 37% of CKD patients were retired,
15% were unemployed or housewife, 10% were unskilled workers, 9% were
professional or skilled worker, and 2% students.
Clinical and bio-chemical characteristics. Based on the subgroup with
clinical data, the aetiology of CKD differed by age group. For patients
over 40 years, commonest causes are type 2 diabetes, hypertension (HTN),
possible analgesic nephropathy and for patients age between 20-40 years,
most common causes are glomerulonephritis, vasculitis and HTN.
Overall, incidence of CKD by area-level SES, are 4 new cases per 1000
population for the most deprived areas (fifth quintile by IMD), and 3 per
1000 for the less deprived areas (third and fourth quintile by IMD) (p<0.03).
Rate of progression was related to area deprivation, with progression more
likely in patients from the most deprived area (73%) than overall (46%)
(p=0.01).
Conclusions: Incidence and rates of progression were higher for patients
from the more deprived areas. Further work is required to explore the
individual level and area level explanations for these associations.
FP190 MORTALITY OF PATIENTS WITH CHRONIC KIDNEY
DISEASE STAGES 1 TO 4 AFTER PERCUTANEOUS
CORONARY INTERVENTION
Sebastjan Bevc 1, Meta Penko 2, Vojko Kanic 2, Radovan Hojs 1. 1Clinical
Department of Internal Medicine, Department of Nephrology; 2Department
of Cardiology, Teaching Hospital Maribor, Slovenia
Introduction and Aims: Cardiovascular (CV) disease is leading cause of
mortality in patients with end-stage renal failure and some recently published
studies indicated that also chronic kidney disease (CKD) is associated with
a higher risk for CV mortality.
The aim of our study was to determine the impact of different stages of
CKD on mortality after percutaneous coronary intervention (PCI) in patients
with acute coronary syndrome (ACS).
Methods: In our study 449 patients, 308 (68.6%) men and 141 (31.4%)
women, with ACS after PCI were included. The mean age of included
patients was 63±11.9 years (ranged from 22 to 96 years). In each patient,
serum creatinine was determined and creatinine clearance was calculated
using the Modification of diet in renal disease (MDRD) formula. According
to the measured GFR patients were enrolled in to the different stages
of CKD. The presence of arterial hypertension and diabetes was defined.
Serum cholesterol (total, HDL and LDL) and triglycerides were measured
by routine laboratory methods. Survival rates were analyzed using Kaplan-
Meier survival curves. Cox regression model was used to assess the influence
of variables that possible had an effect on CV outcomes.
Results: 103 (22.9%) patients had GFR > 89 ml/min/1.73m2 (stage 1 of
CKD), 228 (50.8%) GFR 60-89 ml/min/1.73m2 (stage 2 of CKD), 104
(23.2%) GFR 30-59 ml/min/1.73m2 (stage 3 of CKD) and 11 (2.4%)
patients had GFR 15-30 ml/min/1.73m2 (stage 4 of CKD). Patients were
observed from the date of PCI until their death or from 425 to maximal
770 days. Kaplan-Meier survival analysis showed that mortality after PCI in
patients with ACS increased with the stage of CKD. The risk for CV death
was progressively higher from the patients with stage 1 to stage 4 of CKD.
With Cox multivariable regression model only stages of CKD calculated
with MDRD formula (P=0.001) and total cholesterol (P=0.018) turned out
to be predictors of mortality in our patients.
Conclusions: In patients with ACS after PCI higher stage of CKD was
associated with higher mortality of the patients.
Friday, June 22, 2007 Epidemiology of CKD 1 vi83
FP191 TWO-YEAR COST-EFFECTIVENESS ANALYSIS OF LOW
PROTEIN DIET SUPPLEMENTED WITH ESSENTIAL
AMINO ACIDS IN PATIENTS WITH MODERATE TO SEVERE
CHRONIC RENAL FAILURE
Jonas Hjelmgren, Gunnar Sterner. The Swedish Institute for Health
Economics, IHE, Lund, Sweden; Dept. of Nephrol and Transpl, University
Hospital of Malmö, Malmö, Sweden
Introduction and Aims: A recent Cochrane review of eight clinical trials
including patients with moderate to severe chronic renal failure concluded
that a reduced protein diet has the potential of delaying the need to start
treatment with dialysis.
The objective of this analysis was to to evaluate the cost-effectiveness (cost
per QALY gained) of low protein diet supplemented with essential amino
acids compared with normal diet in patients with moderate to severe renal
failure.
Methods: A Markov model was designed to evaluated renal failure progres-
sion for patients on either low protein or normal diet. The model was based
on monthly probabilities to progress between three discrete health states:
“pre-dialysis”, “pre-dialysis” and “pre-dialysis”. We estimated the average
amount of time (months) spent in each health state, which in turn was
used to estimate total costs and quality adjusted life years (QALYs) during
the two year time perspective. The model was populated with data from
various sources: the eight clinical studies in the Cochrane review (disease
progression and mortality), the Swedish Association of the Pharmaceutical
Industry (drug costs), a regional price list of health care, and from previous
published studies (cost for dialysis and health related quality of life).
Results: Patients receiving low protein diet spent on average 21,7 months
in “pre-dialysis”, 1,9 months in “pre-dialysis”, and 0,4 months as “pre-
dialysis”. The corresponding figures for patients receiving normal diet were
20,1, 3,3 and 0,6 months, respectively. The excess time of 1.4 month in
pre-dialysis together with the reduced mortality resulted in 0.022 more
QALYs (equivalent to 1.1 more weeks in full health) compared to patients
on normal diet. The total average two-year cost for a patient receiving
normal diets and low protein diet amounted to SEK 193 655 and 132 698,
respectively. Hence the cost saving of low protein diet per patient amounted
to SEK 60 687.
Conclusions: Low protein diet could be favourable not only for patients in
terms of less time spent with dialysis and a better quality of life but also in
terms of costs saved for the health care sector.
FP192 PROGRESSION OF CORONARY ARTERY CALCIFICATION
IN PATIENTS WITH CHRONIC KIDNEY DISEASE. ROLE OF
PHOSPHORUS BINDERS
Domenico Russo, Yuri Battaglia, Elisa Buonanno, Ida Miranda,
Carolina Ruocco, Luigi Russo, Anna Scafarto, Vittorio E. Andreucci.
Department of Nephrology, University of Naples “Federico II”, Naples,
Italy
Introduction and Aims: Coronary artery calcifications (CAC) are more
frequent in patients on dialysis (ESRD-patients) than in general population
and rapidly proceed. Progression may cause further cardiovascular events.
Greater prevalence and progression of CAC have been ascribed to exoge-
nous calcium load consequent to high-calcium dialysate, and/or calcium
containing phosphate binders (CCPB). Prevalence and progression of CAC
have been recently reported to be greater in pre-dialysis patients than in
normal subjects; progression was found to be correlated to phosphorus
despite the majority of patients had normal concentration; fatal and not-fatal
cardiovascular events occurred with manifest progression of CAC.
In ESRD-patients progression of CAC can be halted by a non-calcium
containing phosphate binder (sevelamer, S) but not CCPB.
The present study was performed to assess the role of CCPB and S on the
progression of CAC in patients with CKD not on dialysis (CKD-patients).
Methods: Consecutive out-patients (stage 3-4 CKD), homogeneous for
age, biochemical variables and baseline TCS (mean TCS:320-470 Agatston
Units) were randomized to receive S (1600 mg/day) or CCPB (calcium
carbonate, 2 gr/day) throughout the study (18 months). In prior study these
doses did not cause suppression of PTH and/or hypercalcemia. Treated
patients exhibiting hypercalcemia or suppression of PTH exit the study.
Agents affecting mineral metabolism were not allowed. Serum calcium,
phosphorus, i-PTH, homocysteine, C-reactive protein, triglycerides, total
cholesterol, high- and low-density lipoprotein cholesterol were measured
every 3 months. Progression of CAC was assessed measuring total calcium
score (TCS) by computed tomography. Scans were obtained at start (initial)
and end of observation period (final). Data of patients treated with CCPB
and S were compared with those of non-treated CKD-patients (Controls;
C).
Results: Seventy-six patients were enrolled in three groups: C=n.27;
CCPB=n.22; S=n.27.
Initial and final biochemical variables were unchanged but final TCS was
significantly increased in three groups. TCS proceeded by 56% and 55% in
patients treated with C and CCPB, respectively; and by 21% in those treated
with S.
Mean TCS and annualized progression were not different between patients
treated with CCPB and C. No episodes of hypercalcemia were encountered.
PTH remained unchanged. Patients free from CAC at the start remained non
calcified at the end of the study.
Conclusions: Progression of CAC is rapid in CKD-patients despite baseline
normality of mineral metabolism parameters and not exogenous calcium
load. Progression was greater in patients treated with CCPB and C but
small in those treated with S. Study design and small number of patients
did not allow to determine in which manner S contributed to the benefit on
CAC progression. When prescription and reimbursement problem will be
overcame, larger studies are mandatory to better establish the efficacy of
S in reducing CAC progression and eventually morbidity and mortality in
CKD-patients.
FP193 PREVALENCE OF HIV INFECTION IN DIALYSIS CENTRES
IN SPAIN: PRELIMINARY RESULTS OF A SPANISH
SURVEY (YEAR 2006)
Guillermina Barril 1, Joan-Carles Trullas 2, Federic Cofan 3,
Asuncion Moreno 2, Aleix Cases 4, M. Fernandez-Lucas 5,
Jorge Martinez-Ara 6, M. Ceballos 7, J. Garcia-de-Diego 8, M. Muniz 9,
A. Molina 10, M. Martinez-Castelao 11, Jose-Maria Miro 2. 1Nephrology
Service, La Princesa Universitary Hospital, Madrid, Spain; 2Infectious
Diseases Service, Hospital Clinic-IDIBAPS, Barcelona, Spain; 3Renal
Transplant Unit, Hospital Clinic-IDIBAPS, Barcelona, Spain; 4Nephrology
Service, Hospital Clinic-IDIBAPS, Barcelona, Spain; 5Nephrology Service,
Hospital Ramon y Cajal, Madrid, Spain; 6Nephrology Service, La Paz
Universitary Hospital, Madrid, Spain; 7Nephrology Service, Puerta del
Mar Universitary Hospital, Cadiz, Spain; 8Nephrology Service, Hospital
General de Elche, Elche, Spain; 9Nephrology Service, Hospital de Cruces,
Baracaldo, Spain; 10Nephrology Service, Hospital de Donostia, San
Sebastian, Spain; 11Nephrology Service, Bellvitge Universitary Hospital,
Barcelona, Spain
Introduction and Aims: The prognosis of HIV infection has improved
with the widespread use of HAART. The aim of this study was to know
the prevalence of HIV infection in Spanish dialysis patients and the clinical
profile of the potential candidates for renal transplantation.
Methods: Prospective Spanish survey performed during the second trimester
of 2006 using a standardized questionnaire to know the prevalence and
characteristics of HIV infection in dialysis patients in Spain.
Results: 177 (48%) Spanish Dialysis centres have answered the ongoing
survey. 28 centres have HIV infected patients (15’8%). There were 12899
patients included in dialysis programs: 11866 in hemodialysis (HD), 1017 in
peritoneal dialysis (PD) and 16 in home-HD. HIV prevalence was 0.48% (63
HIV positive patients). Prevalence in HD, PD and home-dialysis programs
was 0.42%, 1’2% and 0%, respectively. The 63 HIV-infected patients under
dialysis (50 in HD and 13 in PD) were analysed. Mean (range) age was 46
(29-73) years. 66% of cases were males. HIV risk factors were: parenteral
HIV exposure in 51% (former drug abuse 93%; blood transfusions and
others 7%); high risk sexual behaviour in 30% (heterosexuality 58% and
homosexuality 42%), multiple risk factors in 4.7% and unknown in 14.3%.
Mean (range) time from HIV infection was 11.5 (1-26) years and time on
dialysis was 4.9 (1-26) years. The most frequent aetiology of end-stage
renal disease were glomerulonephritis (35%) followed by diabetes mellitus
(15%). 25% of the diagnosis were proven by biopsy. Nine patients (14%)
were in renal transplant waiting list. 43% of the patients had previous AIDS
defining events and 85% were under HAART regimens. The median (range)
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CD4 T-cell count was 335 cells/mm3 (16-845). 77% had undetectable viral
load. 64% and 5’4% of patients have coinfections with hepatitis C and B
viruses, respectively. 29% of patients have diabetes mellitus and 27% had
previous cardiovascular events.
Conclusions: HIV seroprevalence in Spanish dialysis patients is 0.48%,
being higher in PD than in HD. There are a high percentage of patients
with hepatitis C coinfection, diabetes mellitus and previous cardiovascular
complications. Most of the patients are in an immunological and virological
good situation and under HAART regimens. Some patients are in the renal
transplant waiting list.
FP194 RELATIONSHIP BETWEEN VITAMIN D STATUS,
PARATHYROID HORMONE LEVELS AND BONE MINERAL
DENSITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE
STAGES 3 AND 4
Aristeidis Stavroulopoulos 1 , Christine J. Porter 1, Simon D. Roe 1, David
J. Hosking 2, Michael J.D. Cassidy 1. 1Nottingham Renal and Transplant
Unit; 2Division of Bone and Mineral Metabolism, Nottingham University
Hospitals, City Campus, Nottingham, United Kingdom
Introduction and Aims: Low vitamin D status is associated with secondary
hyperparathyroidism and increased bone turnover in the general population
and can aggravate the hyperparathyroidism of chronic kidney disease (CKD)
patients. It is also correlated to low bone mineral density (BMD), but this
correlation is less clear in CKD patients. Aims of our study were to
investigate these associations in CKD stages 3 and 4 patients, and to identify
significant predictors of BMD in this population.
Methods: Serum 25-hydroxyvitamin D levels (25OHD), BMD at the
femoral neck (FN) and radius, and bone mineral metabolism parameters
were measured in 89 CKD stages 3 and 4 patients. Patients with prior
parathyroidectomy or who had received medication known to affect BMD,
25OHD or parathyroid hormone (iPTH) levels were excluded. Vitamin
D status was defined as follows: serum levels between 40 – 75nmol/L=
insufficiency, < 40nmol/L= deficiency and ≤ 12nmol/L= severe deficiency.
Results: Mean 25OHD levels were 53.8±32.1 nmol/L and correlated
to the severity of proteinuria. Thirty-five patients (39%) had vitamin D
insufficiency, 29 (33%) had vitamin D deficiency and 5 (6%) severe
deficiency. Of the 89 patients, 2 had osteoporosis and 31 had osteopenia
either at femur or radius. Thirty-five patients had low vitamin D and
iPTH above target for the stage of CKD and should require vitamin D
supplementation according to NKF/KDOQI guidelines, but 27 of them had
Ca above 2.37 mmol/L that is the threshold for vitamin D therapy.
In the multiple linear regression analysis, independent predictors for the FN
T score were the iPTH levels (β= -0.36, P< 0.001) and the body mass index
(β= 0.33, P= 0.001), for the model: adjusted R2= 0.196, P< 0.001. For the
radius T score independent predictor was only the severity of proteinuria
(β= -0.28, P= 0.008). Serum 25OHD levels were not directly associated
with BMD, but they were independent predictors of iPTH (β= -0.32, P=
0.001), along with the estimated glomerular filtration rate (β= -0.37, P<
0.001) and the Ca levels (β= -0.2, P= 0.024), for the model: adjusted R2=
0.339, P< 0.001.
Conclusions: Vitamin D insufficiency and deficiency are very common in
CKD stages 3 and 4 population and may indirectly affect (through increase
in iPTH), the bone mineral density of these patients. Further studies are
needed to examine the impact of correction of vitamin D insufficiency
and deficiency on iPTH levels, BMD and fracture risk in CKD population.
Limitation of treatment may be the hypercalcaemia of these patients,
especially if the NKF/DOQI guidelines are to be followed.
FP195 HEPATITIS C VIRUS INFECTION IMPAIRS
HEALTH-RELATED QUALITY OF LIFE IN HEMODIALYSIS
PATIENTS
Baris Afsar 1, Rengin Elsurer 1, Zubeyde Arat 1, Siren Sezer 1,
Bulent Huddam 1, F. Nurhan Ozdemir 1, Mehmet Haberal 2. 1Department of
Nephrology, Baskent University Hospital, Ankara, Turkey; 2Department of
General Surgery, Baskent University Hospital, Ankara, Turkey
Introduction and Aims: Health-related quality of life (HRQOL) is impaired
in hemodialysis (HD) patients. Hepatitis C virus (HCV) infection has
negative impact on HRQOL in patients with normal renal function. However,
HRQOL of HCV positive and negative HD patients was not compared
specifically. We compared HRQOL of HCV positive and negative HD
patients by using Short Form 36 (SF-36).
Methods: Patients performed SF-36 and Beck Depression Inventory (BDI).
Hemodialysis dose was evaluated by single-pool Kt/V (spKt/V). Previous
transplantation history, economical, marital and educational statuses, pres-
ence of coronary artery disease, diabetes and sleep disturbance was noted
and laboratory parameters were recorded.
Results: Totally 173 patients (male/female: 112/61, age: 49.9±14.2 years,
HD duration: 107.1±67.1 months) were included. Eighty-four were HCV
positive, 89 were HCV negative. Hemodialysis duration (141.5±68.9 months
vs 75.4±47.0 months, p:<0.0001), BDI scores (23.1±8.9 vs 20.3±10.1,
p: 0.036), aspartate aminotransferase, (19.7±15.0 U/L vs 14.2±7.1 U/L,
p: 0.002), alanine aminotransferase, (23.6±24.0 U/L vs 14.3±10.8 U/L,
p<0.0001) were higher, low density lipoprotein cholesterol (87.6±31.9
mg/dl vs 101.3±34.0 mg/dL, p:0.007) was lower in HCV positive patients
when compared to HCV negative patients. Other biochemical parameters
were not different between HCV positive and HCV negative patients. After
adjusting for age, HD duration, spKt/V, BDI scores, transplantation history,
economical, marital and educational statuses, coronary artery disease,
diabetes and sleep disturbances, the results of HRQOL showed that HCV
positive patients had worse scores in four subscales of SF-36 namely; general
health (36.9±2.1 vs 44.6±2.0, p:0.016), physical functioning (51.4±3.2 vs
64.3±3.0, p:0.007), physical role (34.6±5.5 vs 51.8±5.2, p:0.036) and
vitality (38.8±2.4 vs 48.2± 2.3, p:0.011) when compared to HCV negative
patients.
Conclusions: HCV positive hemodialysis patients tended to have higher
depression scores than HCV negative patients. HCV infection seemed to
have a negative effect on the health related quality of life in hemodialysis
patients independently.
FP196 RISK FACTORS OF INCREASED ATHEROGENICITY AND
WATER OVERLOAD DURING CHRONIC KIDNEY DISEASE
PROGRESSION ALSO REFLECT CARDIAC REMODELING
Kyriakos Ioannou 1, Evangelia Dounousi 1, Konstantinos Pappas 2,
Apostolos Kelesidis 1, Konstantinos Katopodis 2, Ioannis Tsouchnikas 1,
Nikolaos Kotzadamis 1, Kostas C. Siamopoulos 2, Dimitrios Tsakiris 1.
1Department of Nephrology, General Hospital of Veria, Veria, Greece;
2Department of Nephrology, University of Ioannina, Ioannina, Greece
Introduction and Aims: Cardiovascular morbidity is increasing along with
the progression of chronic kidney disease (CKD). This is due to the
presence of traditional risk factors together with other factors that relate to
renal failure itself. The aim of this study was to investigate the behavior
of fibrinogen, apolipoprotein-A1 (apo-A1) and brain natriuretic peptide
(pro-BNP) in the course of CKD progression and their relation to cardiac
changes detected on echocardiogram.
Methods: In a cross-sectional observation, a population of 223 steady
patients with CKD stages1 to 4 and a “high-risk” population with normal
renal function from the out-patient clinics of two hospitals were studied with
echocardiogram and apo-A1, fibrinogen and pro-BNP were measured in 223,
222 and 114 patients respectively and correlated to the echocardiographic
findings.
Results: Increased fibrinogen levels and decreased levels of apo-A1 are
found in atherosclerotic disease. In our study CKD progression was found
to correlate positively with an increase in fibrinogen levels (p<0,000) and
negatively with the levels of apo-A1 (p=0,005). CKD progression was also
found to correlate positively with an increase in pro-BNP levels (p<0,000),
probably reflecting the inability of the kidneys to maintain water and sodium
balance leading to overload.
Interestingly, all three risk factors correlated also with cardiac changes
detected on echocardiogram. Fibrinogen correlated positively with LV-
mass/BSA (p<0,000), relative wall thickness (RWT) (p<0,000), intraven-
tricular septum (IVS) (p<0,000) and posterior wall (PW) (p<0,000). Pro-
BNP levels also correlated positively with LVmass/BSA (p<0,000), with
end-diastolic (p=0,035) and end-systolic diameter of the LV (p=0,025).In
contrast, Apo-A1 showed a negative correlation with LVmass/BSA (p=0,02),
RWT (p=0,009), IVS (p=0,028) and PW (p=0,001).
Conclusions: In conclusion, the increase of fibrinogen levels and the
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decrease of apo-A1 levels during CKD progression reflect the increased
atherogenicity seen in chronic renal failure, along with significant changes
in cardiac structure. Additionally, the increase in pro-BNP levels probably
reflects the inability of the kidneys to excrete water and sodium overload
and this leads to an increase in LVmass resulting to LV dysfunction with an
increase in LVEDD and LVESD.
FP197 ECHOCARDIOGRAPHIC EVIDENCE OF EARLY CARDIAC
REMODELING DURING CHRONIC KIDNEY DISEASE
PROGRESSION
Kyriakos Ioannou 1, Evangelia Dounousi 1, Konstantinos Pappas 2,
Polychronis Christodoulidis 1 , Apostolos Kelesidis 1,
Konstantinos Katopodis 2, Ioannis Tsouchnikas 1, Kostas C. Siamopoulos 2,
Dimitrios Tsakiris 1. 1Department of Nephrology, General Hospital of
Veria, Veria, Greece; 2Department of Nephrology, University of Ioannina,
Ioannina, Greece
Introduction and Aims: The prevalence of cardiovascular disease (CVD)
in chronic kidney disease (CKD) has been studied in a series of studies.
Up to 80% of patients with end-stage renal failure have abnormal echocar-
diographic findings and this marks a prejudged course of these patients
characterized by an increased CV morbidity and mortality. The aim of this
study was to investigate the time point in the course of CKD that cardiac
remodeling is detectable, so that early interventions will be possible as well
as effective in reversing cardiac damage and by this limiting CV risk.
Methods: For this purpose, in a cross-sectional observation 211 steady
patients with CKD stages1 to 4 from the out-patient clinics of two hospitals
were studied with echocardiogram. There were 105 males (49.8%) and 106
females (50.2%) and their mean age was 64±12 years old. Primary renal
diseases were hypertensive nephrosclerosis 34 (16%), diabetes 30 (14%),
interstitial nephritis 23 (11%), glomerulonephritis 19 patients (9%), and in
62 patients (29%) the PRD was unknown. The distribution of the patients
in the CKD stages were, CKD 1: n=29 (13.7%) with a mean GFR 118±37
ml/min (Cockcroft), CKD 2: n=55 (26.1%), mean GFR 76±8 ml/min, CKD
3: n=75 (35.5%), mean GFR 42±8 ml/min and CKD 4: n=44 (20.9%),
mean GFR 24±4 ml/min.
Results: CKD progression was found to correlate positively with an increase
of left ventricular after adjustment to body surface area LVmass/BSA (stage
1=112 g/m2, stage 2=131 g/m2, stage 3=142 g/m2 and stage 4=169
g/m2, p<0,000). This represented an increase by 17%, 27% and 51% in
LVmass/SA in stage 2, 3 and 4 respectively from stage 1.
Significant increase as CKD was progressed was also observed in relative
wall thickness (p=0,007), intraventricular septum (p=0,023), posterior wall
(p=0,006) and in left ventricular end-diastolic diameter (p=0,031). In
contrast, ejection fraction, fraction shortage and LVESD did not correlation
significantly with CKD progression.
Conclusions: In conclusion, the progression of CKD stages was followed
by a significant remodeling of the heart geometry. Therefore, the well-
established cardiac burden and cardiac remodeling in CKD seems to be a
progressive procedure starting from the early stages. These findings should
prompt early detection as well as proper interventions from the very early
stages of CKD when the structural changes in heart geometry are still
subclinical and probably reversible.
FP198 PREVALENCE AND CROSS-SECTIONAL ASSOCIATIONS
OF A REDUCED ESTIMATED GLOMERULAR FILTRATION
RATE IN THE OVER-75 YEAR OLDS
Dorothea Nitsch 1, Paul J. Roderick 2, Richard Atkins 1, Liam Smeeth 1,
Richard Hubbard 3, Chris Bulpitt 4 , Astrid Fletcher 1. 1Department of
Epidemiology and Population Health, London School of Hygiene &
Tropical Medicine, London, United Kingdom; 2Applied Epidemiology
Group, University of Southampton, Southampton, United Kingdom;
3Department of Clinical Epidemiology, University of Nottingham,
Nottingham, United Kingdom; 4Care of the Elderly, Hammersmith Campus,
Imperial College, London, United Kingdom
Introduction and Aims: Chronic kidney disease (CKD) can be classified
by reduction in the estimated glomerular filtration rate (eGFR). Because
the glomerular filtration rate decreases with age, the clinical significance of
reduced eGFR in older people is uncertain.The aims of this study were to
assess the frequency of CKD in people aged 75 and above, and to evaluate
the associations of different levels of eGFR with morbidity and functional
status.
Methods: Cross sectional study of people aged 75 and over participating in
a cluster randomised trial of health and social assessment of older people
in the community between 1994-8 in the UK. There were 13109 (87%)
participants in 53 general practices who had a serum creatinine measured in
local laboratories at baseline. eGFR was derived from the Modification of
Diet in Renal Disease formula (MDRD). Prevalence of different CKD stages
was calculated stratified by age and gender. Multiple logistic regression
was performed to test for associations with morbidity and functional status
adjusting for age and gender.
Results: Prevalence of CKD for eGFR<60 was 56.1% (95%CI 55.3-
57.0%), for eGFR <45 17.7% (95%CI 17.1-18.4), and for eGFR<30 2.7%
(95% CI 2.4-2.9). Prevalence of all stages of CKD was higher in older
groups, females, and those with cardiovascular co-morbidity and diagnosed
hypertension but not diabetes. The associations with measures of morbidity
and functional impairment increased as eGFR fell, especially once eGFR
was <45. For example the odds ratios in females for anaemia for eGFR
<30 and 30-44 and 45-59 vs reference GFR>60 were 5.69 (4.00-8.12),
1.51 (1.12-2.02) and 1.10 (0.87-4.41) respectively; similar figures for falls at
home and poor physical activity were 1.50 (1.03-2.19) and 2.84 (2.16-3.74),
1.36 (1.14-1.62) and 1.38 (1.17-1.62), 1.06 (0.90-1.26) and 1.00 (0.87-1.16)
respectively.
Conclusions: Stage 3-5 CKD is very common in older people. An eGFR
below 45 identifies a smaller sub-group of older people who are more likely
to have significant comorbidity, impaired functional state, and potentially
reversible consequences such as anaemia. The benefits of identifying older
people with eGFR >45 need to be determined.
FP199 STANDARDISING ESTIMATED GLOMERULAR FILTRATION
RATES (EGFR): DO LABORATORY METHODS REALLY
MATTER IN PRACTICE?
M. Quinn 1, A. Rainey 2, K.J. Cairns 2, A.H. Marshall 2, F. Kee 1,
G. Savage 1, D. Fogarty 3. 1Department of Public Health and Epidemiology,
The Queen’s University of Belfast, Belfast, United Kingdom; 2Centre for
Statistical and Operational Research (CenSSOR), The Queen’s University
of Belfast, Belfast, United Kingdom; 3Department of Nephrology, The
Queen’s University of Belfast, Belfast, United Kingdom
Introduction and Aims: Chronic kidney disease (CKD) guidelines have
focused on the utility of the modified 4-variable MDRD equation (traceable
by isotope dilution mass spectrometry IDMS). This formula accounts for
variance in creatinine measured by an analyser different to that used when
the original MDRD equation was devised.
To assess theoretically and in practice the effect sizes of IDMS correction
over the 4-variable MDRD equation in eGFR calculation with a range of UK
creatinine methods and the subsequent impact of this on CKD prevalence.
Methods: MATLAB was used to generate a range of creatinine data (30-
300umol/l) for male and female patients aged 20-100 years. The maximum
differences between the IDMS and MDRD equations for all 14 UK
laboratory techniques were explored with an averaged (IDMS + MDRD)-
eGFR less than 60mls/min and also 30mls/min. Similar procedures were
applied to 712,540 samples (reflecting 5 creatinine methods in Northern
Ireland), belonging to patients 18 years+, to explore graphically maximum
differences in techniques. CKD prevalence using both estimation equation
was compared.
Results: Simulated creatinine data indicates that the majority of creatinine
procedures in the UK demonstrate small differences between the IDMS and
MDRD methods in stages 4 and 5 CKD (where the averaged maximum
difference for all laboratory methods was 1.27mls/min for females and
1.59mls/min for males). The MDRD equation deviated furthest from the
IDMS results for the Endpoint Jaffe method: the maximum difference of
9.93mls/min for females and 5.42mls/min for males occurred at extreme
ages and in those with eGFR reflecting stage 3 or higher disease. The real
data graphically agreed with the theoretical results.
Using existing data 93,870 patients yielded a first MDRD eGFR<60mls/min
in 2001. 66,429 (71%) had a second test >3months later of which 47,093
(71%) continued to have an eGFR<60mls/min. This resulted in an estimated
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crude prevalence of 3.97% for laboratory detected CKD in adults using
the MDRD equation which reduced to 3.69% when applying the IDMS
equation. Over 95% of this difference in prevalence was explained by
older females with stage 3 CKD with data close to the stage 2 interface
reemphasizing the need for further research into the subcategorisation of
stage 3 CKD.
Conclusions: Improved accuracy of eGFR is obtainable by using IDMS
corrected eGFR especially in early stage CKD; however our data suggests
this will have little practical impact on stages 4-5 considering the current
referral guidelines.
FP200 LEFT VENTRICULAR HYPERTROPHY IN PREDIALYSIS
CHRONIC KIDNEY DISEASE: IMPACT OF
CARDIOMUSCULAR BIOMARKERS
Tomonori Kimura 1, Ken-ichiro Iio 1,2, Yoshitsugu Obi 1,
Terumasa Hayashi 1. 1Nephrology, Rinku General Medical Center,
Izumisano Municipal Hospital, Izumisano, Osaka, Japan; 2Geriatric and
Nephrology, Osaka University School of Medicine, Suita, Osaka, Japan
Introduction and Aims: Cardiovascular disease is a major cause of death in
patients with advanced stages of chronic kidney disease (CKD), including
dialysis patients. Left ventricular hypertrophy (LVH) is an independent
predictor of mortality and morbidity in patients with end-stage renal disease
and is present in over 70% of patients commencing dialysis. However, only
a few studies of LVH are available about the patients before the start of
dialysis treatment. The purpose of this study is to evaluate the prevalence
and clinical correlates of LVH in patients with advanced stages of CKD.
Methods: We performed a cross-sectional study of 92 patients (48 men;
mean age 64±9 (34-87) years) with renal diseases but history of neither
cardiovascular diseases nor arrhythmia. The mean creatinine clearance was
19.3±8.0 mL/min. We calculated left ventricular mass index (LVMi) using
the American Society of Echocardiography cube formula method regressed
to anatomic validation. LVH was difined as LVMi greater than 131g/m2 in
men and greater than 100g/m2 in women. Circulating levels of human atrial
natriuretic peptide (hANP) was measured as a cardiovascular biomarker.
Results: LVH was present in 54% of the population studied. The prevalence
of LVH is significantly increased with progression of renal decline: 21%
in stage 3, 40% in stage 4, and 71% in stage 5 (P < 0.001). Univariate
analyses revealed that creatinine clearance, hemoglobin, systolic blood
pressure hANP, and intact PTH (P < 0.01). Stepwise logistic regression
analysis demonstrated that hANP is selected as the independent risk factor.
Conclusions: LVH is highly prevalent in patients with advanced stages
of CKD, which is associated with severity of renal impairment. hANP is
identified as a modifiable factor as predictor of LVH. We suggest that strict
control of body fluid could prevent the progression of LVH, and as a result,
could attenuate the risk of cardiovascular events in CKD.
FP201 DETECTION OF CHRONIC KIDNEY DISEASE IN
“HEALTHY” ELDERLY PEOPLE
David Nava, Fabiola Martin del Campo, Susan Ordaz, Liliana Gonzalez,
Laura Cortes-Sanabria, Enrique Rojas-Campos, Hector Martinez-Ramirez,
Alfonso Cueto-Manzano. Unidad de Investigacion Medica en
Enfermedades Renales, Hospital de Especialidades, CMNO, IMSS,
Guadalajara, Jalisco, Mexico
Introduction and Aims: Renal function physiologically decreases with
age; on the other hand, elderly population is increasing dramatically among
ESRD patients. Frequently, a reduced renal function in the elderly is
attributed to normal ageing, and other causes are not investigated; thus, an
good opportunity to identify and treat renal disease at early stages is lost.
Few renal function data in apparently healthy elderly people have been
published. Therefore, the aim of this study was to determine the prevalence
and presence of renal disease risk factors in people older than 60 years
otherwise considered as healthy.
Methods: We included subjects older than 60 years, considered as “healthy”
and assisting to a program to prevent chronic diseases (PREVENIMSS) in a
Primary Health-Care Unit (UMF 34). Individuals with transient albuminuria,
or any documented or strongly suspected renal, urinary or systemic disease
affecting renal function (particularly diabetes and hypertension) were
excluded. All subjects were evaluated for microalbuminuria (microAlbU)
by dipstick (micraltest II®) in the first voiding urine sample; in 24-h urine
collections, albuminuria was quantitatively measureed by nephelometry.
Nephropathy was defined as presence of albuminuria, indepently of GFR,
or presence of a GFR <60 mL/min/1.73m2, independently of albuminuria.
Results: Eighty-two subjects, aged 67±6 years, have been evaluated. From
the total, 5% had microAlbU and 7% had a reduced GFR; considering
both variables, 12% of the evaluated population had nephropathy (early
nephropathy in all cases). The presence of macroAlbU or GFR <30
mL/min/1.73m2 was not observed. Results of renal function are shown in
the table. Although no significant differences were observed comparing
subjects with normal function vs those with nephropathy, the latter tended
to be older (70±7 vs 67±6 years), had higher diastolic blood pressure
(78±5 vs 67±6 mmHg) and higher proportion of males (44% vs 35%) than
those with normal renal function. No differences in the use of non-steroidal
anti-inflammatory drugs were found between groups, but a high frequency
in the use of these drugs was observed in both subjects with and without
nephropathy (75% vs 73%).
GFR (ml/min/1.73 m2) Prevalence (%) Albuminuria
NO YES
≥90 23 18 1
60-89 70 54 3
30-59 7 6 0
Total (%) 100 95 5
Conclusions: The percentage prevalence of early renal disease in subjects
older than 60 years, otherwise considered as healthy in our setting, was
12%, whereas the presence of isolated microAlbU was 5% and reduced
GFR was 7%. Individuals with nephropathy, tended to be older, have higher
diastolic blood pressure and higher male sex proportion compared to those
with normal renal function.
FP202 PRESENCE AND RISK FACTORS OF CORONARY ARTERY
CALCIFICATION IN PATIENTS WITH AND WITHOUT
DIABETES AND CHRONIC KIDNEY DISEASE STAGES 3
AND 4
Aristeidis Stavroulopoulos 1 , Christine J. Porter 1, Michael J.D. Cassidy 1,
David J. Hosking 2, Kate Pointon 3 , Simon D. Roe 1. 1Nottingham Renal
and Transplant Unit; 2Division of Bone and Mineral Metabolism;
3Radiology Department, Nottingham University Hospitals, City Campus,
Nottingham, United Kingdom
Introduction and Aims: In the general population the presence and extent
of coronary artery calcification (CAC) have been used for the non-invasive
diagnosis of coronary artery stenosis and for prognostic purposes. Studies
in chronic kidney disease (CKD) patients, especially in end stage renal
disease, have reported extremely high CAC prevalence with CAC scores up
to ten times higher than expected for age and sex. The presence of diabetes
seems to increase the risk of CAC, however to date no direct comparisons
have been reported between CKD patients with and without diabetes. Aim
of this study was to describe the prevalence and extent of CAC in CKD
stages 3 and 4 patients comparing patients with and without diabetes and
identify risk factors. Another aim of the study was to determine if the
presence of peripheral artery calcification (PAC) would assist in identifying
patients positive for CAC.
Methods: A cross-sectional study was carried out in 112 patients of both
sexes, aged between 18-65 years with CKD stages 3 and 4, 54 with
and 58 without diabetes, all asymptomatic for heart disease. CAC was
detected by multi-slice computed tomography (MSCT), and PAC by plain
foot radiography. Demographic and laboratory data were also collected and
analysed.
Results: Prevalence of CAC was 74% and 46.5% in CKD patients with
and without diabetes respectively (40/54 vs. 27/58, P= 0.003) and the two
groups were matched for age and sex. In the multivariate analysis for
the whole group, age, diabetes and obesity were the major predictors of
CAC. Patients with diabetes had higher CAC scores [159 (1-4074) vs. 47
(2-1196), P= 0.002], with more vessels affected [3 (1-5) vs. 2 (1-5), P=
0.03], and in the presence of diabetes men and women had the same risk
for CAC. Severity of renal dysfunction was a predictor of CAC in the
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patients without diabetes, but not when diabetes was present. Smoking was
associated with the extent of CAC, especially in patients with diabetes.
Phosphate levels were predictive of CAC in patients without diabetes, and
parathyroid hormone levels were associated with the extent of CAC in the
non-diabetic population and when all CKD patients were considered.
The presence of PAC on plain radiography identified patients with CAC on
MSCT, with a sensitivity of 73%, a specificity of 28%, a positive predictive
value of 44% and a negative predictive value of 76% indicating that it was
not an adequate alternative screening marker for identifying patients with
CAC.
Conclusions: CAC is common in CKD stages 3 and 4 patients, especially
in those with diabetes. Further studies are needed to establish if lifestyle
modifications (smoking cessation and weight management) and therapeutic
strategies targeting iPTH and phosphate, can affect the prevalence and
severity of CAC, delay its progression and finally reduce the very high
cardiovascular disease risk seen in CKD patients.
FP203 FACTORS INFLUENCING EXERCISE PROTEINURIA IN
YOUNG HEALTHY PERSONS
Dominika Partycka, Magdalena Leszczynska, Zuzanna Ejsmont,
Anna Rozumko, Agnieszka Sendrowicz, Marta Kozuchowska,
Marcin Zietkiewicz, Dominik Swieton, Wojciech Wolyniec,
Boleslaw Rutkowski. Department of Nephrology, Transplantology and
Internal Medicine, Medical University of Gdansk, Gdansk, Poland
Introduction and Aims: The intensive physical activity is known as a
cause of benign proteinuria. Although in the literature exist some studies
describing exercise proteinuria (EP) the explanation of this phenomemon is
not fully explained. The aim of the study was to estimate frequency of EP
among healthy young participants of long distance march.
Methods: 115 participants of March on Orientation “Harpagan”, all ama-
teurs, who took at least 50-km walk in the forest had performed urinanalysis
with test strips.
Results: 1. EP was found in 26 persons (22,6%), in all cases values
reaching 30mg/dl. 2. There was no correlation between presence of EP
and age of participants and durations of exercise. Specific gravity (SG) and
pH of urine, as well as frequency of erytrocyturia and bilirubinuria were
similar in both groups. Ketonuria was more frequent in participants with EP
(tabl.1). 3. Ketones were found in 75 participants (65,2%). There was not
difference between participants with or without ketonuria with reference to
age, gender and duration of exercise. Those with ketonuria had higher SG
and lower pH of urine, proteinuria was common (tab. 2). 4. 54 participants
answered questionnaire concerning diet and time of recovery. Participants
with ketonuria took less fluids and kalories and were more exhausted after
march than those without ketones in urine.
The characteristic of persons with and without proteinuria
Proteinuria Mean Women Duration of SG of Ketones pH of
age exercise urine urine
Yes 29,3y 12% 14,6h 1025 88,5% 5,4
No 27,8y 10% 15,6h 1023,3 58,4% 5,8
The characteristic of persons with and without ketonuria
Ketones Duration SG of pH of Proteinuria Food intake during Fluids Time to
of exercise urine urine exercise (kcal) (L) recovery
No 15,37 h 1019 6,2 7% 2169,79 2,85 1,14 days
Yes 15,32 h 1026,26 5,44 30,67% 1940,54 2,49 1,72 days
Conclusions: Some interesting conclusions can be drawn from this very
simple study. 1. After long exhausting march proteinuria occurs only in 20%
of young healthy persons. 2. EP is alwalys at minimal range (30mg/dl). 3.
Presence of EP is not correlated with duration of exercise but rather with
improper diet and may be improper training.
FP204 THE RELATION BETWEEN INSULIN RESISTANCE AND
ANTHROPOMETRIC VALUES IN NONDIABETIC
HAEMODIALYSIS PATIENTS
Eyup Koc, Fatma Ayerdem Ebinc, Ruya Mutluay, Kadriye Altok Reis,
Ulver Boztepe Derici, Yasemin Erten, Arinsoy Turgay, Aydan Yuksel.
Department of Nephrology, Gazi University School of Medicine, Ankara,
Turkey
Introduction and Aims: It has been known the role of hyperinsulinemia in
inflammatory process and its association with anthropometric measurements.
We aimed to identify that in nondiabetic haemodialysis (HD) patients, which
anthropometric values are related most closely to insulin resistance (IR).
Methods: Five-two nondiabetic HD patients aged 47.7±14 (22-75) were
enrolled. Each subject’s weight, height, waist, hip and arm circumference,
biceps and triceps skin fold were measured; body mass index (BMI) and
waist to hip ratio were calculated. Percentage of body fat was analyzed
by bioelectrical impedance. In fasting blood samples, complete blood
count, insulin, glucose, uric acid, albumin, transferrin, ferritin, HsCRP were
measured. IR was calculated by homeostasis model assessment (HOMA)
and cut-off point was accepted 2.7.
Results: Of all patients 14 (26.9%) were female, 38 (73.1%) were male.
Mean duration of HD was 59.1±42.9 month (2-170), 13 (25.5%) patients
had overweight and obesity (BMI >25 kg/m2), 16 (30.8%) had increased
body fat (female ≥33%, male ≥22%), 22 (42.3%) had IR.
Serum level of insulin and HOMA index were significantly correlated with
BMI (r=0.32, p=0.023; r=0.28, p=0.048, respectively) and arm circumfer-
ence (r=0.32, p=0.024; r=0.28, p=0.046, respectively). Hip circumference
was only associated with the level of insulin (r=0.32, p=0.029). Other
anthropometric measurements did not relate to insulin level and HOMA
index.
BMI, hip and arm circumference in patients with IR were significantly
more than the other (p=0.031, p=0.008, p=0.037; respectively). Lymphocyte
count in this group was less (p=0.036). The levels of uric acid, albumin,
transferrin, ferritin and HsCRP did not differ between groups.
The correlation between anthropometric measurements with serum insulin level and
HOMA index
Serum insulin level HOMA index
r value p value r value p value
Body mass index 0.32 0.023 0.28 0.48
Percentage of body fat 0.21 NS 0.19 NS
Waist circumference 0.24 NS 0.21 NS
Hip circumference 0.32 0.029 0.27 NS
Arm circumference 0.32 0.029 0.28 0.046
Biceps skin fold 0.16 NS 0.13 NS
Triceps skin fold 0.11 NS 0.09 NS
HOMA: Homeostasis model assessment.
Conclusions: Regarding to IR, in nondiabetic HD patients, BMI and arm
circumference are more important anthropometric measurements.
FP205 ULTRASONOGRAPHIC RENAL DIMENSIONAL
PARAMETERS HELP PREDICT RENAL OUTCOME IN
PATIENTS WITH CHRONIC RENAL INSUFFICIENCY
Domenico Mancuso, Nicolino Comi, Michele Andreucci, Cinzia Donato,
Pierangela Presta, Giorgio Fuiano. Nephrology, University Magna Graecia,
Catanzaro, Italy
Introduction and Aims: Ultrasonography (US) of the kidney and urinary
tract has become the primary modality for the evaluation of urinary diseases
since number, location, size and shape of the kidneys, and the collecting
system are accurately assessed. It has been shown that renal length and
volume are correlated with age and body weight (BW), so that a variability
of 5% is present in adults. Since renal length, volume and echogenicity are
considered potential surrogate markers of single kidney function, US has
been proposed as a screening modality to evaluate patients with chronic
renal insufficiency (CRIpts). However, as yet, no study has specifically
evaluated the correlation between renal US parameters and GFR levels
when age, BW, BP and other parameters supposed to be correlated to GFR
are simultaneously considered.
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Methods: Aim of the study is to verify the relationship between renal US
and functional parameters in CRIpts (135 pts, stage 2-4 KDOQI) and in a
control population (C: 315 healthy volunteers from the staff of two local
hospitals). The same sample was evaluated after a two-year follow-up.
Results: Basal study. Mean age was 49.8±13 yrs, 47.22% male. Arterial
hypertension was found in 63.7% of CRI pts and in none of C. Mean
serum creatinine was 1.11 mg/dL in C group (ranging 0.67-1.23) and
3.75 mg/dL in CRF group (ranging 1.8-7.7). As compared to C, CRI pts
presented significantly reduced the renal longitudinal diameter and volume
in all CRI stages, while the transversal diameter and cortical thickness were
significantly reduced only in pts with stage 3 and 4.
Follow-up. Observation lasted 24±2 months. CRF pts were divided in
4 quartiles according to their basal renal volume. In CRF group 23 pts
presented 1 or 2 event failure (reduction >30% of basal GFR and/or start of
hemodialysis) and 14 died (3 of these had started RDT). The relationship
between these events and clinical, laboratory and US parameters was
evaluated by calculating the hazard ratio for unit increase. Reduction of
cortical thickness (in III and IV quartiles) and kidney volume (in all
quartiles) were identified as risk-factors, as well as the increases in SBP
(in all quartiles), DBP(in IV quartile), CaxP product, PTH (in III and IV
quartiles), CRP and daily proteinuria in all quartiles. By contrast, normal
serum albumine and Hb levels were identified as protective factors. By
multivariate analysis, we showed that the every 10 cm3 of kidney volume
reduction there is an increase of 18% of risk-events in C vs 38% in CRF
pts. The reduction of cortical thickness increases the risk of events by 2% in
C vs 21% in CRF patients. Both the risk of progression to ESRD and death
were inversely related to the kidney volume (p<0.001 for both the events)
at baseline.
Conclusions: Our data establish important correlation of US dimensional
parameters with decline-rate of GFR and other non- or traditional risk factors
in course of CRI. The simultaneous combination of morpho-dimensional
and functional parameters could help to improve the accuracy of the
follow-up in patients with CRI, with possible therapeutical and prognostic
implications.
FP206 RENAL INSUFFICIENCY IN BONE METASTASIS CANCER
PATIENTS: PREVALENCE AND IMPLICATIONS ON
ANTICANCER DRUGS MANAGEMENT. SUBGROUP
ANALYSIS OF THE IRMA STUDY
Vincent Launay-Vacher 1, Stéphane Oudard 2, Nicolas Janus 1,
Christophe Le Tourneau 3, Olivier Rixe 4, Xavier Pourrat 5,
Joseph Gligorov 6 , Philippe Beuzeboc 3, Jean-François Morere 7,
Gilbert Deray 1. 1Nephrology, GH Pitié-Salpêtrière, Paris, France;
2Medical Oncology, Hôpital Européen Georges Pompidou, Paris, France;
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France; 6Medical Oncology, Hôpital Tenon, Paris, France; 7Medical
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Introduction and Aims: The IRMA study reported the high prevalence of
renal insufficiency (RI) in 4684 solid tumour patients, with a glomerular
filtration rate (GFR) <90 ml/min for 50-60%. Furthermore, 80.1% were
receiving nephrotoxic anticancer drugs and 79.9% drugs necessitating
dosage adjustment. We present the results for IRMA patients with bone
metastasis (BM).
Methods: Subgroup analysis of IRMA patients with BM. Data collected:
sex, age, weight, serum creatinine (SCR), bone metastasis (BM) and
anticancer drugs. The prevalence of SCR>110 μmol/L was assessed.
GFR was estimated with Cockcroft-Gault (CG) and abbreviated MDRD
(aMDRD) formulae. Drugs necessitating dosage adjustment and those
potentially nephrotoxic were identified. Chi-square test was used to compare
the prevalence of RI between patients with BM and patients without, for all
patients and for breast cancer (BC) ones.
Results: 1000 patients (BC 577) with BM were included: median age
60, mean 59.8, weight 66 kg, 659 women. The prevalence of SCR>110
μmol/L was 8.3%. That of GFR<90 ml/min was 57.9% with CG and 54.7%
with aMDRD. 83.4% of treated patients received at least one drug needing
dosage adjustment (or no data) and 69% received at least one nephrotoxic
drug. The prevalence of RI was not statistically different between patients
with or without BM. However, the prevalence of RI was significantly higher
in BC patients with BM as compared to BC patients without BM (62.1
versus 56.7%, p=0.04).
RI stages in IRMA patients with bone metastasis according to K/DOQI-K/DIGO
classification
Stage of RI GFR (mL/min or mL/min/1.73m2) CG aMDRD
Stage 1 >=90 34.1 38.3
Stage 2 60-89 36.4 41.7
Stage 3 30-59 19.9 11.4
Stage 4-5 <30 1.6 1.6
Data not available 8 7
RI: Renal Insufficiency; GFR: Glomerular Filtration Rate; CG: Cockcroft-Gault
Conclusions: RI is highly frequent in cancer patients with BM. Appropriate
evaluation of renal function necessitates CG or aMDRD calculation. In
those patients, and especially in breast cancer patients with BM, anticancer
drugs should be cautiously selected regarding their potential renal toxicity
and need for dosage adjustment.
FP207 BIOPSY IN OLDER PATIENTS. IT IS RECOMMENDED?
Rosa Ramos, Luís Carreras, Carlota González, Rafael Poveda, Josep
M. Grinyó. Nephrology, Hospital of Bellvitge, L’Hospitalet, Barcelona,
Spain
Introduction and Aims: During the last three decade (1974-2004), the
percentage of patients older than 65 years who have been diagnosed by
renal biopsy have increased progressively: 1974-1984: 6.8%; 1984-1194:
19.49%; 1994-2204: 24.78%.
Methods: In this period of time we have performed 1922 renal biopsies of
native kidney in our centre.
Results: 60.5% Male/39.5% Female.320 patients (16.64%) were equal or
older than 65 years (group A). 1602 (83.36%) were younger than 65 years
(group B). Kidney biopsy in group A were taking in 39% because of
nephrotic syndrome, in 33% due to rapidly renal insufficiency and in 11%
due to nephrotic proteinuria range. In group B were significantly lower
(17.7%;3.35%;17.3%). The final diagnosis is showed on table 1.
Table 1
>65 y Group A <65 y Group B p
Vasculitis 17.8 2.71 p<0.05
Amiloydosi 6.66 2.05 p<0.05
Renal myeloma 4.12 0.58 p<0.05
Membranous nephropathy 10.5 8.47 ns
Focal segmentary scle 9.2 16.28 p<0.05
IgA nephropathy 6.6 19.44 p<0.05
Conclusions: Age of patients is cause of worsening renal function and
also is accompanied of higher incidence secondary nephropathies. A high
number of this secondary nephropathy could be treated effectively, for
this reason we believe that renal biopsy must be performed even in older
patients.
FP208 CARDIOVASCULAR IMPLICATIONS OF COMMUNITY
BASED DETECTION OF REDUCED GFR
Carmen Bernis 1, Amelia Gonzalez-Gamarra 2, Sergio Ruiz-Alonso 2 ,
Ana Diez 3, Yolanda Hernandez 1, Jose Antonio Sanchez-Tomero 1.
1Nephrology, Hospital Universitario La Princesa, Madrid, Spain; 2Primary
Healthcare, Area II Madrid, Madrid, Spain; 3Biochemistry, Hospital
Universitario de la Princesa, Madrid, Spain
Introduction and Aims: Chronic kidney disease is an asymptomatic condi-
tion managed by primary care physicians. We think that the use of Primary
Healthcare Information System (OMI –AP, Stacks, Madrid community)
and outpatients’ laboratory database to identify people with low GFR
may be an effective strategy to prevent kidney disease and cardiovascular
complications.
Methods: We studied in the sanitary area 2 of Madrid community a
population of 64481 people older than 14 years, (48664 younger than
65 and 15.817 older than 65) corresponding to 3 primary care centres.
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Primary care database records were used to identify age, gender and clinical
features of people who had creatinina measurement, between April 2004
and April 2006, performed in the hospital area laboratory as outpatients.
The laboratory used the modified kinetic Jaffe assay with coefficient of
variation of <3%. GFR was calculated by the abbreviated MDRD formula
GFR ml/min/1.73 (Manjunath Curr Opin Nephrol Hypertens 2001).
Results: We found 33.662 creatinina test performed in 19059 different
adults or 29% of the population. The proportion of the population with renal
testing increased with age; it was 47.2% of those older than 65yr and 23.8%
of patients younger.
10.093 patients, 15.2% of the entire population and 52.8% of those with test
performed had Ccr between 60 and 90ml/m; 2824, 4.25% of population and
11.8% of tested had Ccr <60. Considering older than 65yr we found 28%
of population and 59.4% of those with test performed with Ccr 60-90ml/m;
12.2% (25.6%) with Ccr <60.
The incidence of cardiovascular complications was higher in the group with
Ccr<60: 65.1%HTA, 15.4% diabetics, 11.5 ischemic cardiopathy, 7.4%
stroke, V.S 28.8%, 8.8%, 4.02%,2.2% in group with Ccr >60 (p<0.05).
Conclusions: Identifying individuals with reduced a GFR using laboratory
database and Primary Healthcare Information System is a promising strategy
to prevent kidney disease and cardiovascular complications.
FP209 MULTIFOCAL FUNGAL INFECTIONS AT DIFFERENT
STAGES OF CHRONIC KIDNEY DISEASE
Piotr Kurnatowski 1, Ilona Kurnatowska 2, Agata Drozdowska 1,
Michal Nowicki 2. 1Department of Biology and Medical Parasitology,
Medical University, Lódz´, Poland; 2Department of Nephrology,
Hypertension and Kidney Transplantation, Medical University, Lódz´,
Poland
Introduction and Aims: Patients with chronic kidney disease are believed
to be much more susceptible to fungal infections than healthy individuals due
to coexisting immunity disorders, frequent invasive diagnostic/therapeutic
procedures and the wide use of broad-spectrum antibacterial agents for
bacterial infections. The aim of the study was to evaluate prevalence of
fungi and its species in patients with chronic kidney disease.
Methods: In this cross-sectional study, 50 patients with chronic renal disease
(22 M and 28 F; mean age 56.6±2.12 yrs) with GFR <60 ml/min/m2, not
yet on dialysis (CKD), 56 patients (35 M and 21 F; mean age 55.4±3.8
yrs) on chronic haemodialysis (HD) and 30 healthy (18 M and 12 F; mean
age 49.1±5.6 yrs) subjects without history of kidney disease were included.
All patients did not show any clinical signs of fungal infections and were
not treated with antibacterial agents for at least 4 weeks. Specimens for
mycological examinations were taken from the oral cavity, faeces and urine
(if available). In order to evaluate morphological and biochemical features
of fungi the following methods were applied: 1. macrocultures in solid
Sabouraud’s medium, 2. direct microscopic slides and microcultures in
different media, 3. API 20 C AUX test.
Results: 385 samples for the mycological examinations were collected and
161 fungal strains were isolated from the samples. The fungi were isolated
from 54 HD patients (96.4%), 32 CKD (64.0%) and 19 (63.3%) healthy
subjects; the most frequently from oral cavity in HD (88.9%) and CKD
patients (84.4%) and from faeces in healthy subjects (53.3%). The fungi
in urine were detected in 4 HD patients (from all 33 samples collected
from patients with residual diuresis), 10 CKD and none in healthy subjects.
Monofocal mycosis was found in 29 HD (51.8%), 14 CKD (43.7%) and
11 healthy subjects (36.6%), and bifocal in 24 (44.4%), 15 (30.0%) and
8 (26.6%) subjects, respectively. The pathogens were identified the most
frequently from ontocenoses of the oral cavity and the rectum. Trifocal
infections (in oral cavity, rectum and urinary tract) were found in only 1
HD and 4 CKD patients. The fungi were isolated from 64.3% CKD patients
with 30 >GFR <60, 60.0% with 15 > GFR <30 and 83.3% with GFR <15
ml/min/m2 (p<0.001). From all isolated strains 156 belonged to the genus
Candida, 2 to the genus Saccharomyces and the remaining 2 to the genera:
Cryptococcus and Geotrichum. Candida albicans was the most frequently
isolated pathogen from all groups of patients.
Conclusions: Prevalence of fungal infection in non dialysis patients with
chronic kidney diseases is similar to healthy subjects and increases in
patients with more advanced CKD and those on HD. Fungal infections in
haemodialysis patients are common and frequently more than monofocal.
FP210 RENAL INSUFFICIENCY AS A RISK FACTOR FOR
DEVELOPMENT OF ADVERSE DRUG REACTIONS
Galya Stavreva 1, Dobromir Dossev 2, Vasil Todorov 2, Russi Marev 1.
1Pharmacology and Clinical Pharmacology, Medical University, Pleven,
Bulgaria; 2Nephrology and Hemodialysis, University Hospital, Pleven,
Bulgaria
Introduction and Aims: Adverse drug reactions (ADRs) cause significant
patient morbidity, mortality, and cost. Patients with chronic renal insuffi-
ciency (CRI), including hemodialysis patients are at high risk for ADRs and
drug-drug interactions. The frequency of ADRs increases with number of
medications need, the age of the patient, the number of comorbid conditions
and the degree of renal dysfunction.
A 3-month prospective pharmacovogilance study was managed in Clinic
of Nephrology and Hemodialysis among hospitalized patients to: (i) detect
ADRs as cause of admissions and manifested during hospital stay; (ii) study
characteristics of ADRs; (iii) assess the importance of CRI as a risk factor.
Methods: All suspected ADRs were collected by clinical pharmacologist
and nephrologists via everyday patient examination, review the patient
charts, all medicationsand laboratory measurements. The prevalence of
ADR, types (Edwards&Aronson classification), causality (Naranjo index)
and severity of ADR, length of hospital stay, avoidability, and outcome were
evaluated.
Results: Patients were 58,0 (range 18-81) years old, had 4,8±2,0 comorbid
conditions, were taking 5,93±1,97 (range 2- 14) medications, 52,47% had
renal insufficiency. Among 223 inpatients, we found 17,04% with ADR;
incidence – 197,3‰. 70,45% were determined to be Type A, 25% - Type B
and 2,27% - Type C and D according to Edwards&Aronson. 55,16% (n=21)
of patients with ADR had CRI (4 patients – I degree; 7 – II degree; 10 –
III degree). Five severe ADRs were detected; all were occurred in patients
with CRI; 4 in hemodialysis patients.
Conclusions: The number of ADRs experienced by patients with renal
insufficiency was not significantly greater than by patients without CRI, but
ADRs were more severe. Most ADRs were predictable and possibly avoid-
able, considering the degree of CRI and co-morbidity; pharmacokinetics
and nephrotoxicity of drugs; limitation of polypharmacy.
FP211 HEMODIALYSIS PATIENTS: CORONARY CALCIUM
DEPOSITS AND PTH SERUM LEVELS
Giorgio Coen 1, Micaela Manni 2, Alessandro Balducci 2,
Daniela Mantella 3, Andrea Pierantozzi 4, Luigi Pellegrino 5,
Andrea Romagnoli 5, Stefano Condò 6, Giorgio Splendiani 6. 1Dept. of
Nephrology, Ospedale Israelitico, Rome, Italy; 2Dept. of Nephrology, San
Giovanni, Rome, Italy; 3Dept. of Nephrology, San Camillo, Rome, Italy;
4Dept. of Lab., Policlinico Tor Vergata, Rome, Italy; 5Dept. of Radiology,
Policlinico Tor Vergata, Rome, Italy; 6Dept. of Nephrology, Policlinico Tor
Vergata, Rome, Italy
Introduction and Aims: Decreased bone turnover, as in adynamic bone
disease (ABD), is considered a risk factor of vascular calcifications (London
G et al 2004), due to decreased buffering of calcium-phosphate and
consequent extraskeletal mineral overload.
Methods: Bone turnover in CKD is strictly linked to PTH serum levels. In
our experience, in the PTH range 0 to 150, 50% of patients (pts) have ABD
and 40% have a normal bone turnover, while all patients with PTH >500
pg/ml have increased bone turnover. This study has been carried out in 197
pts on HD, mean age 61±12 years, M/F 1070/90, subjected to Multislice
CT for evaluation of coronary calcifications. Pts were divided in groups of
increasing intact PTH serum levels: A, 0-150 pg/ml (24 pts); B, 150-300 (33
pts); C, 300-600 (40 pts) and D, > 600 pg/ml (38 pts). The groups were dif-
ferent for HD age (p<0.02), serum phosphate (p<0.001), CaxP (p<0.001).
Results: There was no difference in serum CRP and Fetuin-A among the
groups. Average (±SD) Agatston score values of coronaries were: group
A, 842.14±1210, B, 896.82±1085; C, 1405.37±1950; D, 2170.46±3307,
with p<0.05 (ANOVA). In a multivariate regression analysis with coronary
score as dependent variable, age (p<0.0001), HD age (p<0.005) and
PTH (p<0.001) were independent significant risk factors. In conclusion
iPTH serum levels 0-150, consistent with low to normal bone turnover,
are associated to lower coronary score values. More severe coronary
calcification scores are found in higher PTH groups.
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Conclusions: Together with other known variables, PTH is an independent
risk factor of coronary calcifications.
FP212 NATIONAL RENAL HEALTHCARE PROGRAM IN URUGUAY
Laura Solá 1, Emma Schwedt 1, Pablo Ríos 1,2, Nelson Mazzuchi 1. 1Renal
Healthcare Committee, Montevideo, Uruguay; 2Renal Healthcare, National
Fund of Resources, Montevideo, Uruguay
Introduction and Aims: Uruguay is a developing country with an estab-
lished program (PR) for renal replacement therapy (RRT) for all patients
(Pt) with end stage renal disease (ESRD) since 1980 (incidence: 149 pmp in
2005). A Pilot PR targeted to the Public assistance population of Montevideo
was tried out supported by the Health Ministry and the National Fund of
Resources, to guide the feasibility of a National Renal Healthcare Program
(NRHP).
Methods: Improve Renal Healthcare (RH) in the entire population (POP)
by the implementation of a NRHP for public and private assistance system
by steps.
Specific Objectives:
1. Promote education for RH and healthy lifestyles in the POP
2. Integrate RH into the first level of assistance to promote early detection
of CKD and set optimal timing of referral
3. Optimize Pt care in all stages to prevent or delay progression of CKD.
The expected CKD prevalence for people aged 20 or older (extrapolated
from US data and adjusted for Uruguayan ESRD prevalence) is 6.7%.
Methods. The planned activities were to:
1) Inform the POP about healthy lifestyles and risk factors, through Primary
Health Centers (PHC) teams, and massive diffusion media.
2) Integrate the RH in the First Level of assistance: a) designate a
nephrologist (ND) to attend 2 hours a week for each 10000 POP aged
20 years and over. The Pt are referred by primary-care physicians (PCPs)
or directly from the laboratory; b) Train the PCPs, dietitians and nurses
on prevention and detection of at risk POP through education courses and
guidelines; c) Plan the ND visits in a reference counter-reference system,
depending on CKD stage, and d) Provide the renoprotective drugs.
3) Keep a longitudinal Registry of Pt with eGFR < 60 ml/min/1.73m2,
proteinuria >300 mg/day or microalbuminuria >30 mg/day in diabetics
4) Reduce drop out with an electronic alarm that informs when a Pt miss an
appointment.
5) Derive Stage 4 Pt to a Pre-dialysis Clinic, staffed by a formal multidis-
ciplinary team (ND, Psychiatrist, dietitians, social worker, vascular surgery
and nurses) committed to educate, give social and psychological support,
and indicate the timely creation of the access for the selected dialysis
modality.
6) Sign a contract of agreement between the NFR and the private and puplic
healthcare institutions (HCI) progressively. For achieving comparable results
it includes the implementation of the standardization of serum creatinine
assay in each HCI with the Committee for Standardization and Quality
Control (by calibration to an isotope dilution mass spectrometry (IDMS)
reference method.
Results: The PR has been evaluated according to Structure indicators (IN)
(hours of ND assigned to the target POP); Process IN (average number of
new P per month); and Results IN (prevalence of CKD, P distribution by
sex, age, stage and etiology, quality of care). The PR impact is measured by
GFR changes, ESRD rate, and mortality rate.
Conclusions: The strategic framework of the NRHP has a continuous
approach across primary, secondary and tertiary levels of prevention. Its
feasibility has been proven by a pilot PR that now allowed the generalization
of a NHRP in Uruguay.
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FP214 ESTIMATION OF URINARY MONOCYTE
CHEMOATTRACTANT PROTEIN-1 (MCP-1) AS A MARKER
OF RENAL INJURY IN TYPE II DIABETES MELLITUS
Salwa Ibrahim, Laila Rashed. Department of Medicine, Cairo University,
Cairo, Egypt; Department of Medical Biochemistry, Cairo University,
Cairo, Egypt
Introduction and Aims: Diabetic nephropathy (DN) is the leading cause
of end stage renal disease in western world. Increased number of interstitial
macrophages has been observed in biopsies from patients with DN. Mono-
cyte chemoattractant protein-1 (MCP-1) is the strongest known chemotactic
fact for monocytes and is upregulated in DN. We examined urinary level of
MCP-1 in type 2 DM patients to assess the possible correlation between its
level and the parameters of renal injury.
Methods: Urinary MCP-1 level was assessed in 75 patients with type 2 DM
(25 with & 25 without microalbuminuria and 25 with macroalbuminuria
and renal impairment) and compared with matched healthy control subjects.
HBA1c and estimated glomerular filtration rate derived from MDRD
equation were examined in the study groups in relation to the urinary
MCP-1.
Results: Urinary MCP-1 level was significantly higher in patients with micro
and macroalbuminuria (167.41±50.23 and 630.87±318.10 ng/g creatinine
respectively) as compared with normoalbuminuric patients and healthy
controls (63.85±21.15 and 61.50±24.81 ng/g creatinine, P<0.05). MCP-1
correlated positively with urine albumin excretion rate (UAE) (r=0.75,
P<0.05), HBA1c (r=0.55, P<0.05) and inversely with GFR (r=-0.60,
P<0.05).
Conclusions: The study findings suggest that hyperglycemia is associated
with increased urinary levels of MCP-1 that is closely linked to renal
damage as reflected by proteinuria and GFR levels. Collectively, these
findings suggest that MCP-1 is involved in the pathogenesis of diabetic
nephropathy throughout its variable stages.
FP215 VALGANCICLOVIR PROPHYLAXIS FOR 6 MONTHS
PREVENTS CMV-INDUCED DISEASE IN 96% OF KIDNEY
TRANSPLANT RECIPIENTS
Diego Cantarovich, Magali Giral, Jacques Dantal, Gilles Blacho,
Jean-Paul Soulillou. Nephrology and Clinical Immunology, ITERT, Nantes
University Hospital, Nantes, France
Introduction and Aims: The benefits of CMV prophylaxis following kidney
transplantation (Tx) are well established. However, it is not clear how long
this prophylaxis must be given and whether should be applied universally
or to selected patients (pts). Our objectives were to compare the occurrence
and impact of CMV disease in 3 consecutive eras in pts receiving the same
immunosuppressive regimen and transplanted and followed in the same
institution by the same medical team.
Methods: 799 adult kidney Tx pts were selected since 1996 at the time
of MMF was introduced in our unit. Period 1 (1996-1998) included 325
pts (80% primary Tx); no prophylaxis against CMV was given. Period 2
(1999-2004) included 323 pts (59% primary Tx); Valacyclovir was given
for 6 months to all pts excepted D-/R-. Period 3 (2005-ongoing) included
149 pts (84% primary Tx); Valganciclovir was given for 6 months to all pts
excepted D-/R-. All pts received induction with either ATG or anti-CD25
moAb, MMF, CNI and a steroid taper regimen (withdrawal at 2 months).
CMV D/R serological status was not different among the 3 periods.
Results: The incidence of CMV disease was 27% in pts without any
prophylaxis, 11% with valacyclovir (p<0.0001) and 4% with valganciclovir
(p<0.0001). The difference between valacyclovir and valgancyclovir was
also statistically different (p<0.02). Onset of the disease significantly
changed from 1.9 months in the absence of prophylaxis to 3.6 months with
valacyclovir and 8.3 months with valgancicloir (p<0.01). CMV disease was
similarly encountered in D+/R-, D-/R+ and D+/R+ pts. No case of CMV
disease was observed in valgancyclovir D-/R- pts (3% with valacyclovir).
Patient survival was significantly lower in the era without prophylaxis as
compared to pts receiving valacyclovir (11 vs 4% mortality; p<0.003). Graft
loss was also lower (21 vs 9%; p<0.001). In the valganciclovir era, pts death
was 3% (p<0.01 compared to non prophylaxis) and graft loss 3% (p<0.001
